Artificial Intelligence (AI) in Healthcare Market by Function (Imaging, Robotics, AI Scribe, Telehealth, CDS, Precision Medicine, Radiation, RCM, Cybersecurity), Tools (ML, NLP, Computer Vision), End User (Hospital, ASC, Payer) - Global Forecast to 2031
The global artificial intelligence (AI) in healthcare market is projected to reach USD 194.79 billion by 2031 from USD 36.67 billion in 2026, at a CAGR of 39.7% during the forecast period. The AI in healthcare market is growing rapidly as hospitals and health systems increasingly deploy AI solutions to improve clinical efficiency, reduce physician burnout, and enhance patient outcomes. For example, in 2025, the Cleveland Clinic rolled out Ambience Healthcare’s AI documentation platform across its US outpatient network after evaluating the technology across more than 80 specialties. The solution was adopted by over 4,000 clinicians within 15 weeks of deployment, enabling documentation for more than one million patient encounters. Additionally, in January 2026, Aultman Health System deployed Nabla’s ambient AI solution across hundreds of clinicians through integration with Oracle Cerner, while AtlantiCare reported a 50% reduction in documentation time after implementing Oracle Health’s Clinical AI Agent. As real-world adoption continues to expand across hospitals, clinics, and health systems, AI is expected to play an increasingly critical role in shaping the future of healthcare delivery worldwide.
By deployment, the cloud-based models segment is expected to register the highest growth during the forecast period.
The AI in healthcare market is categorized into three deployment models: on-premises, cloud-based, and hybrid. The cloud-based models segment holds the largest share due to their scalability, cost-effectiveness, and accessibility. Cloud-based models facilitate real-time data processing and collaboration. They enable seamless integration, secure data storage, and rapid deployment, making them particularly well-suited for healthcare providers and payers. They provide faster, more reliable care while maintaining high-quality standards. Cloud-based AI solutions are becoming increasingly popular due to their cost-effectiveness, scalability, and support for remote access. These solutions enable seamless integration and real-time analytics. The growing adoption of telehealth and advancements in healthcare IT infrastructure further drive the demand for cloud-based models.
By end user, the hospitals & clinics segment dominated the artificial intelligence (AI) in healthcare market for healthcare providers in 2025.
By end user, the artificial intelligence (AI) in healthcare market for healthcare providers is segmented into hospitals & clinics, ambulatory surgical centers, home healthcare agencies & assisted living facilities, diagnostic & imaging centers, pharmacies, and other healthcare providers. The hospitals & clinics segment accounted for the largest share of the artificial intelligence (AI) in healthcare market for healthcare providers. This is attributed to the increasing demand for personalized medicines, precise diagnostics & surgical planning, growth in minimally invasive procedures, and the requirement for interoperability with existing systems. AI-based healthcare solutions enhance diagnostic accuracy, streamline operations, and personalize care in hospitals and clinics. They automate administrative tasks, predict patient outcomes, and enable faster decision-making with real-time data analysis. AI also supports remote monitoring, optimizes resources, and reduces costs by minimizing unnecessary treatments.
The Asia Pacific is expected to register the highest growth during the forecast period.
The artificial intelligence (AI) in healthcare market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is the fastest growing in the AI in healthcare market, driven by rapid healthcare digitalization, increasing investments in artificial intelligence, expanding adoption of electronic health records (EHRs), and strong government support for digital health initiatives. Countries such as China, India, Singapore, Japan, and South Korea are actively integrating AI into diagnostics, medical imaging, clinical decision support, and hospital workflow management. For instance, in February 2026, India launched its Strategy for AI in Healthcare (SAHI), establishing a national framework for the responsible and large-scale adoption of AI across the healthcare ecosystem. Healthcare providers across the region are also expanding AI adoption. In Singapore, the Ministry of Health is scaling generative AI for clinical documentation and AI-powered imaging solutions across the public healthcare system, while hospitals such as Ng Teng Fong General Hospital are using AI-enabled tools to improve patient management and care delivery.
The breakdown of primary participants is as mentioned below:
The prominent players operating in the artificial intelligence (AI) in healthcare market include Koninklijke Philips N.V. (Netherlands), Microsoft Corporation (US), Siemens Healthineers AG (Germany), NVIDIA Corporation (US), Epic Systems Corporation (US), GE Healthcare (US), Medtronic (US), Oracle (US), Veradigm LLC (US), Merative (IBM) (US), Google (US), Cognizant (US), Johnson & Johnson (US), Amazon Web Services, Inc. (US), SOPHiA GENETICS (US), Riverian Technologies (US), Terarecon (ConcertAI) (US), Solventum Corporation (US), Tempus (US), Viz.ai (US). These companies adopted strategies such as product launches, product updates, expansions, partnerships, collaborations, mergers, and acquisitions to strengthen their market presence in the artificial intelligence (AI) in healthcare market.
Research Coverage
The report analyzes the artificial intelligence (AI) in healthcare market and estimates the market size and future growth potential of various market segments by offering, function, application, deployment model, tool, end user, and region. The report also analyses factors (such as drivers, restrains, opportunities, and challenges) affecting market growth. It evaluates the opportunities and challenges for market stakeholders. The report also examines micromarkets in terms of their growth trends, prospects, and contributions to the total artificial intelligence (AI) in healthcare market. The report forecasts revenue for the market segments across five major regions. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report
This report will help established firms, as well as new entrants/smaller firms, gauge the market pulse, which, in turn, will help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the following strategies to strengthen their market positions.
This report provides insights on:
By deployment, the cloud-based models segment is expected to register the highest growth during the forecast period.
The AI in healthcare market is categorized into three deployment models: on-premises, cloud-based, and hybrid. The cloud-based models segment holds the largest share due to their scalability, cost-effectiveness, and accessibility. Cloud-based models facilitate real-time data processing and collaboration. They enable seamless integration, secure data storage, and rapid deployment, making them particularly well-suited for healthcare providers and payers. They provide faster, more reliable care while maintaining high-quality standards. Cloud-based AI solutions are becoming increasingly popular due to their cost-effectiveness, scalability, and support for remote access. These solutions enable seamless integration and real-time analytics. The growing adoption of telehealth and advancements in healthcare IT infrastructure further drive the demand for cloud-based models.
By end user, the hospitals & clinics segment dominated the artificial intelligence (AI) in healthcare market for healthcare providers in 2025.
By end user, the artificial intelligence (AI) in healthcare market for healthcare providers is segmented into hospitals & clinics, ambulatory surgical centers, home healthcare agencies & assisted living facilities, diagnostic & imaging centers, pharmacies, and other healthcare providers. The hospitals & clinics segment accounted for the largest share of the artificial intelligence (AI) in healthcare market for healthcare providers. This is attributed to the increasing demand for personalized medicines, precise diagnostics & surgical planning, growth in minimally invasive procedures, and the requirement for interoperability with existing systems. AI-based healthcare solutions enhance diagnostic accuracy, streamline operations, and personalize care in hospitals and clinics. They automate administrative tasks, predict patient outcomes, and enable faster decision-making with real-time data analysis. AI also supports remote monitoring, optimizes resources, and reduces costs by minimizing unnecessary treatments.
The Asia Pacific is expected to register the highest growth during the forecast period.
The artificial intelligence (AI) in healthcare market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is the fastest growing in the AI in healthcare market, driven by rapid healthcare digitalization, increasing investments in artificial intelligence, expanding adoption of electronic health records (EHRs), and strong government support for digital health initiatives. Countries such as China, India, Singapore, Japan, and South Korea are actively integrating AI into diagnostics, medical imaging, clinical decision support, and hospital workflow management. For instance, in February 2026, India launched its Strategy for AI in Healthcare (SAHI), establishing a national framework for the responsible and large-scale adoption of AI across the healthcare ecosystem. Healthcare providers across the region are also expanding AI adoption. In Singapore, the Ministry of Health is scaling generative AI for clinical documentation and AI-powered imaging solutions across the public healthcare system, while hospitals such as Ng Teng Fong General Hospital are using AI-enabled tools to improve patient management and care delivery.
The breakdown of primary participants is as mentioned below:
- By Company Type: Tier 1 (32%), Tier 2 (44%), and Tier 3 (24%)
- By Designation: Directors (30%), Managers (34%), and Others (36%)
- By Region: North America (40%), Europe (28%), Asia Pacific (20%), Latin America (7%), and the Middle East & Africa (5%)
The prominent players operating in the artificial intelligence (AI) in healthcare market include Koninklijke Philips N.V. (Netherlands), Microsoft Corporation (US), Siemens Healthineers AG (Germany), NVIDIA Corporation (US), Epic Systems Corporation (US), GE Healthcare (US), Medtronic (US), Oracle (US), Veradigm LLC (US), Merative (IBM) (US), Google (US), Cognizant (US), Johnson & Johnson (US), Amazon Web Services, Inc. (US), SOPHiA GENETICS (US), Riverian Technologies (US), Terarecon (ConcertAI) (US), Solventum Corporation (US), Tempus (US), Viz.ai (US). These companies adopted strategies such as product launches, product updates, expansions, partnerships, collaborations, mergers, and acquisitions to strengthen their market presence in the artificial intelligence (AI) in healthcare market.
Research Coverage
The report analyzes the artificial intelligence (AI) in healthcare market and estimates the market size and future growth potential of various market segments by offering, function, application, deployment model, tool, end user, and region. The report also analyses factors (such as drivers, restrains, opportunities, and challenges) affecting market growth. It evaluates the opportunities and challenges for market stakeholders. The report also examines micromarkets in terms of their growth trends, prospects, and contributions to the total artificial intelligence (AI) in healthcare market. The report forecasts revenue for the market segments across five major regions. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report
This report will help established firms, as well as new entrants/smaller firms, gauge the market pulse, which, in turn, will help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the following strategies to strengthen their market positions.
This report provides insights on:
- Analysis of key drivers (rapid proliferation of AI in healthcare sector and growing need for improved healthcare services), restraints (shortage of skilled AI professionals handling AI-powered solutions and lack of standardized frameworks for AI and ML technologies), opportunities (strategic partnerships and collaborations among healthcare companies and AI technology providers and increase in focus on developing human-aware AI systems), challenges (concerns regarding data privacy and lack of interoperability) are factors contributing the growth of the artificial intelligence (AI) in healthcare market.
- Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and software launches in the artificial intelligence (AI) in healthcare market.
- Market Development: Comprehensive information on the lucrative emerging markets, offering, function, application, deployment, tool, end user, and region
- Market Diversification: Exhaustive information about software portfolios, growing geographies, recent developments, and investments in the artificial intelligence (AI) in healthcare market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global artificial intelligence (AI) in healthcare market, such as Koninklijke Philips N.V. (Netherlands), Microsoft Corporation (US), Siemens Healthineers AG (Germany), NVIDIA Corporation (US), and Epic Systems Corporation (US).
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
2 EXECUTIVE SUMMARY
2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS IN AI IN HEALTHCARE MARKET
2.4 HIGH-GROWTH SEGMENTS
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
3.1 AI IN HEALTHCARE MARKET OVERVIEW
3.2 AI IN HEALTHCARE MARKET, BY APPLICATION AND REGION
3.3 AI IN HEALTHCARE MARKET: GEOGRAPHIC SNAPSHOT
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Increasing need for early detection and diagnosis of diseases
4.2.1.2 Exponential growth in data volume and complexity due to surging adoption of digital technologies
4.2.1.3 Significant cost pressure on healthcare service providers with increasing prevalence of chronic diseases
4.2.1.4 Rapid proliferation of AI in healthcare sector
4.2.1.5 Growing inclination toward precision medicine and personalized care
4.2.2 RESTRAINTS
4.2.2.1 Reluctance among medical practitioners to adopt AI-based technologies
4.2.2.2 Shortage of skilled AI professionals handling AI-powered solutions
4.2.2.3 Lack of standardized frameworks for AI and ML technologies
4.2.3 OPPORTUNITIES
4.2.3.1 Rising demand for AI-driven clinical decision support systems
4.2.3.2 Increasing focus on developing human-aware AI systems
4.2.3.3 Strategic partnerships and collaborations among healthcare companies and AI technology providers
4.2.3.4 Rising adoption of AI-enabled medical imaging and diagnostics
4.2.4 CHALLENGES
4.2.4.1 Inaccurate predictions due to scarcity of high-quality healthcare data
4.2.4.2 Concerns regarding data privacy
4.2.4.3 Lack of interoperability between AI solutions offered by different vendors
4.3 UNMET NEEDS AND WHITE SPACES
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
5 INDUSTRY TRENDS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 THREAT OF NEW ENTRANTS
5.1.2 THREAT OF SUBSTITUTES
5.1.3 BARGAINING POWER OF SUPPLIERS
5.1.4 BARGAINING POWER OF BUYERS
5.1.5 INTENSITY OF COMPETITIVE RIVALRY
5.2 MACROECONOMIC OUTLOOK
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS AND FORECAST
5.2.3 TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY
5.3 VALUE CHAIN ANALYSIS
5.4 ECOSYSTEM ANALYSIS
5.5 PRICING ANALYSIS
5.5.1 INDICATIVE PRICING FOR AI IN HEALTHCARE, BY APPLICATION (2025)
5.5.2 INDICATIVE PRICING FOR AI IN HEALTHCARE MARKET, BY REGION (2025)
5.6 KEY CONFERENCES AND EVENTS, 2026–2027
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.8 INVESTMENT AND FUNDING SCENARIO
5.9 CASE STUDY ANALYSIS
5.9.1 ACCELERATING LUNG CANCER DIAGNOSIS THROUGH AI ACROSS NHS HOSPITALS
5.9.2 STRENGTHENING PATIENT TRUST THROUGH DIGITAL PATIENT ENGAGEMENT SOLUTIONS
5.9.3 OPTIMIZING PATIENT ENGAGEMENT AND COMMUNICATION WITH TRUBRIDGE PATIENT CONNECT
5.10 IMPACT OF US TARIFF – OVERVIEW
5.10.1 INTRODUCTION
5.10.2 KEY TARIFF RATES
5.10.3 PRICE IMPACT ANALYSIS
5.10.4 IMPACT ON COUNTRIES/REGIONS
5.10.4.1 US
5.10.4.2 Europe
5.10.4.3 Asia Pacific
5.10.5 IMPACT ON END USERS
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1 KEY EMERGING TECHNOLOGIES
6.1.1 MACHINE LEARNING AND DEEP LEARNING
6.1.2 NATURAL LANGUAGE PROCESSING
6.1.3 COMPUTER VISION
6.2 COMPLEMENTARY TECHNOLOGIES
6.2.1 CLOUD COMPUTING
6.2.2 DIGITAL TWINS
6.2.3 ROBOTIC PROCESS AUTOMATION
6.3 ADJACENT TECHNOLOGIES
6.3.1 BLOCKCHAIN
6.3.2 AUGMENTED REALITY AND VIRTUAL REALITY
6.3.3 INTERNET OF THINGS
6.4 PATENT ANALYSIS
6.4.1 PATENT PUBLICATION TRENDS FOR AI IN HEALTHCARE LANDSCAPE
6.4.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
6.5 FUTURE APPLICATIONS
6.5.1 AI-DRIVEN PRECISION MEDICINE
6.5.2 REAL-TIME CLINICAL DECISION SUPPORT WITH GENERATIVE AI
6.5.3 DISEASE PREDICTION AND EARLY INTERVENTION THROUGH PREDICTIVE ANALYTICS
6.5.4 AI-POWERED VIRTUAL HEALTH ASSISTANTS AND DIGITAL CARE NAVIGATION
6.5.5 ADVANCING AUTONOMOUS AI AGENTS FOR HEALTHCARE WORKFLOW AUTOMATION
7 REGULATORY LANDSCAPE
7.1 REGIONAL REGULATIONS AND COMPLIANCE
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2 REGULATORY FRAMEWORK
8 CUSTOMER LANDSCAPE AND BUYER BEHAVIOR
8.1 INTRODUCTION
8.2 DECISION-MAKING PROCESS
8.3 KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR EVALUATION CRITERIA
8.3.1 KEY STAKEHOLDERS IN BUYING PROCESS
8.3.2 BUYING CRITERIA
8.4 ADOPTION BARRIERS AND INTERNAL CHALLENGES
8.5 UNMET NEEDS OF VARIOUS END USERS
8.5.1 UNMET NEEDS
8.5.2 END-USER EXPECTATIONS
8.6 MARKET PROFITABILITY
8.7 IMPACT ON COUNTRIES/REGIONS
8.7.1 US
8.7.2 EUROPE
8.7.3 ASIA PACIFIC
8.8 IMPACT ON END USERS
9 AI IN HEALTHCARE MARKET, BY FUNCTION
9.1 INTRODUCTION
9.2 DIAGNOSIS & EARLY DETECTION
9.2.1 PRE-SCREENING
9.2.1.1 Early detection, better outcomes, and cost-effective care associated with pre-screening to boost market
9.2.2 IVD
9.2.2.1 IVD market, by technology
9.2.2.1.1 Immunoassays
9.2.2.1.1.1 Potential to enhance biomarker detection and laboratory automation to accelerate demand
9.2.2.1.2 Clinical chemistry
9.2.2.1.2.1 Ability to improve laboratory efficiency and diagnostic accuracy to spur adoption
9.2.2.1.3 Molecular diagnostics
9.2.2.1.3.1 Pressing need to identify viral and bacterial pathogens in infectious diseases to facilitate adoption
9.2.2.2 IVD market, by application
9.2.2.2.1 Image analysis & interpretation
9.2.2.2.1.1 Rising focus of pathologists on analyzing tissue samples for detecting abnormalities at faster rate to fuel segmental growth
9.2.2.2.2 Biomarker discovery & analysis
9.2.2.2.2.1 Elevating adoption of precision medicine to create growth opportunities
9.2.2.2.3 Other IVD applications
9.2.3 DIAGNOSTIC IMAGING
9.2.3.1 Diagnostic imaging market, by application
9.2.3.1.1 Disease interpretation & report analysis
9.2.3.1.1.1 Proficiency in identifying disease-specific patterns and correlating findings across multiple data sources to fuel adoption
9.2.3.1.2 Image captioning & annotation
9.2.3.1.2.1 Increasing use of machine learning for automated image captioning to foster market growth
9.2.3.1.3 Image reconstruction
9.2.3.1.3.1 Greater emphasis of healthcare facilities on optimizing imaging workflows and increasing scanner throughput to augment adoption
9.2.3.1.4 Other diagnostic imaging applications
9.2.3.2 Diagnostic imaging market, by modality
9.2.3.2.1 Magnetic resonance imaging
9.2.3.2.1.1 Escalating adoption of AI across MRI workflows to enhance diagnostic confidence and improve scanner utilization to augment market growth
9.2.3.2.2 Computed tomography
9.2.3.2.2.1 Urgent need for efficient diagnosis to provide the right treatments to drive market
9.2.3.2.3 X-ray imaging
9.2.3.2.3.1 Development of innovative AI-based X-ray imaging solutions to drive market
9.2.3.2.4 Ultrasound
9.2.3.2.4.1 Increasing investments in developing AI-assisted ultrasound imaging auto-assessment tools to expedite market growth
9.2.3.2.5 Nuclear imaging
9.2.3.2.5.1 Integration of AI algorithms for quick detection and monitoring of abnormalities to facilitate market growth
9.2.3.2.6 Other diagnostic imaging modalities
9.2.4 RISK ASSESSMENT & PATIENT STRATIFICATION
9.2.4.1 Critical need to identify high-risk patients and predict their disease progression risks to boost demand
9.2.5 DRUG ALLERGY ALERTING
9.2.5.1 Significant focus on improving accuracy and speed of identifying allergic reactions to contribute to market growth
9.2.6 OTHER DIAGNOSIS & EARLY DETECTION FUNCTIONS
9.3 TREATMENT PLANNING & PERSONALIZATION
9.3.1 PERSONALIZED TREATMENT PLANNING
9.3.1.1 Precision medicine & genomic analysis
9.3.1.1.1 Adoption of AI-based software for personalized treatment decisions and improved outcomes to propel market
9.3.1.2 Predictive models for treatment response
9.3.1.2.1 Ability to personalize therapies, improve outcomes, and minimize adverse effects to fuel growth
9.3.1.3 Treatment recommendation systems
9.3.1.3.1 Competency in offering personalized, evidence-based treatment options to spike demand
9.3.2 PHARMACOLOGICAL THERAPY
9.3.2.1 Drug response prediction
9.3.2.1.1 Increasing use of AI-powered drug response prediction in oncology and chronic disease management to drive market
9.3.2.2 Dosing & administration
9.3.2.2.1 Capability of AI-based dosing models to adjust doses in real-time based on individual patient responses to spur demand
9.3.2.3 Other pharmacological therapy functions
9.3.3 SURGICAL THERAPY
9.3.3.1 Preoperative imaging & 3D modeling
9.3.3.1.1 Widening use of AI-driven 3D modeling in orthopedic, cardiovascular, neurological surgeries to fuel market growth
9.3.3.2 Intraoperative guidance & robotics
9.3.3.2.1 Inclination toward minimally invasive surgeries and faster patient recovery to boost implementation
9.3.3.3 Postoperative analysis & recovery
9.3.3.3.1 Ability to predict recovery patterns, identify risks, and provide personalized rehabilitation plans to boost demand
9.3.4 RADIATION THERAPY
9.3.4.1 Motion synchronization & auto contouring
9.3.4.1.1 Need for precise delivery of radiation and minimum exposure to surrounding healthy tissues to reinforce segmental growth
9.3.4.2 Real-time adaptive treatment delivery
9.3.4.2.1 Growing focus on consistent treatment accuracy and clinical outcome optimization to strengthen demand
9.3.4.3 Response assessment & quality assurance
9.3.4.3.1 Ability of AI solutions to analyze medical images, treatment plans, and dosimetric data to accelerate demand
9.3.4.4 Other radiation therapy functions
9.3.5 BEHAVIORAL THERAPY & PSYCHOTHERAPY
9.3.5.1 Virtual counseling & chatbots
9.3.5.1.1 Potential to improve patient communication, engagement, and service efficiency to expand implementation
9.3.5.2 Progress monitoring & feedback
9.3.5.2.1 Increasing use of smart wearables and mobile health apps to drive market
9.3.5.3 Follow-up & long-term support
9.3.5.3.1 Widespread adoption of telemedicine platforms to drive market expansion
9.3.6 IMMUNOTHERAPY
9.3.6.1 Real-time patient data monitoring
9.3.6.1.1 High demand for proactive healthcare management to foster segmental growth
9.3.6.2 Response & side-effect prediction
9.3.6.2.1 Need for earlier detection of treatment-related risks across drugs and vaccines to support segmental growth
9.3.6.3 Relapse prediction & long-term management
9.3.6.3.1 Necessity for continuous patient monitoring and risk stratification to fuel demand
9.3.7 OTHER TREATMENT PLANNING & PERSONALIZATION FUNCTIONS
9.4 PATIENT ENGAGEMENT & REMOTE MONITORING
9.4.1 SYMPTOM MANAGEMENT & VIRTUAL ASSISTANCE
9.4.1.1 Constant requirement for symptom management in chronic diseases to accelerate adoption of AI-powered apps
9.4.2 TELEHEALTH & REMOTE PATIENT MONITORING
9.4.2.1 Increasing adoption of mobile health apps and wearable devices to augment segmental growth
9.4.3 HEALTHCARE ASSISTANCE ROBOTS
9.4.3.1 Competency in improving quality of care and reducing burden on healthcare workers to promote adoption
9.4.4 MEDICATION REMINDERS
9.4.4.1 Capability to deliver medication guidance, personalized health coaching, and care coordination to foster demand
9.4.5 PATIENT EDUCATION & EMPOWERMENT
9.4.5.1 Need to improve treatment adherence and enhance self-management to drive market
9.4.6 OTHER PATIENT ENGAGEMENT & REMOTE MONITORING FUNCTIONS
9.5 POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE
9.5.1 RECURRENCE MONITORING
9.5.1.1 Advancing post-treatment care through intelligent recurrence monitoring to support market growth
9.5.2 LONG-TERM OUTCOME PREDICTION
9.5.2.1 Greater emphasis on predicting disease recurrence and survival chances to improve uptake of AI-powered medical devices
9.5.3 MENTAL HEALTH & SUPPORT SYSTEMS
9.5.3.1 Rising focus on emotional well-being of patients with critical illness to support segmental growth
9.6 PHARMACY MANAGEMENT
9.6.1 EPRESCRIBING
9.6.1.1 Urgent need to replace paper-based prescription to electronic platform to expedite adoption of ePrescribing solutions
9.6.2 MEDICATION MANAGEMENT
9.6.2.1 Innovative medication management programs between healthcare professionals and pharmacists to encourage segmental growth
9.6.3 PHARMACY AUDIT & ANALYSIS
9.6.3.1 Demand for operational excellence and improved patient care outcomes across pharmacies to create growth opportunities
9.6.4 OTHER PHARMACY MANAGEMENT FUNCTIONS
9.7 DATA MANAGEMENT & ANALYTICS
9.7.1 RISING FOCUS OF HEALTHCARE ORGANIZATIONS ON DEVELOPING PERSONALIZED TREATMENT PLANS TO SUPPORT SEGMENTAL GROWTH
9.8 AI SCRIBE
9.8.1 GROWING NEED TO IMPROVE CLINICIAN PRODUCTIVITY AND REDUCE DOCUMENTATION TIME TO STRENGTHEN AI SCRIBE DEPLOYMENT
9.9 CLINICAL DECISION SUPPORT SYSTEMS
9.9.1 INCREASING NEED FOR EVIDENCE-BASED CLINICAL DECISION-MAKING TO SPIKE ADOPTION
9.10 ADMINISTRATIVE
9.10.1 PATIENT REGISTRATION & SCHEDULING
9.10.1.1 Rising adoption of self-service patient registration solutions to contribute to segmental growth
9.10.2 PATIENT ELIGIBILITY & AUTHORIZATION
9.10.2.1 Growing demand for faster prior authorization workflows to facilitate market growth
9.10.3 REVENUE CYCLE MANAGEMENT
9.10.3.1 Significant need to reduce claim denials and reimbursement delays to reinforce demand
9.10.4 WORKFORCE MANAGEMENT
9.10.4.1 Growing need to optimize healthcare workforce utilization to create lucrative opportunities
9.10.5 SUPPLY CHAIN & INVENTORY MANAGEMENT
9.10.5.1 Strong focus on reducing inventory costs and waste to bolster market growth
9.10.6 COMPLIANCE & DOCUMENTATION
9.10.6.1 Increasing regulatory compliance requirements in healthcare to escalate demand for AI-based compliance & documentation
9.10.7 HEALTHCARE WORKFLOW MANAGEMENT
9.10.7.1 Surging need for end-to-end workflow automation to foster segmental growth
9.10.8 ASSET MANAGEMENT
9.10.8.1 Pressing need to improve equipment availability and reduce downtime to heighten demand for AI-based asset management
9.10.9 CUSTOMER RELATIONSHIP MANAGEMENT
9.10.9.1 Growing focus on personalized patient engagement to boost segmental growth
9.10.10 FRAUD DETECTION & RISK MANAGEMENT
9.10.10.1 Rising financial losses to drive investment in AI-based proactive risk management solutions
9.10.11 CYBERSECURITY
9.10.11.1 Critical requirement to protect sensitive patient data to propel demand for AI-powered threat detection solutions
9.10.12 OTHER ADMINISTRATIVE FUNCTIONS
10 AI IN HEALTHCARE MARKET, BY OFFERING
10.1 INTRODUCTION
10.2 INTEGRATED SOLUTIONS
10.2.1 ESCALATING DEPLOYMENT OF ENTERPRISE-WIDE AI PLATFORMS TO CONTRIBUTE TO SEGMENTAL GROWTH
10.3 NICHE/POINT SOLUTIONS
10.3.1 GROWING ADOPTION OF SPECIALIZED AI APPLICATIONS FOR TARGETED CLINICAL AND ADMINISTRATIVE TASKS TO DRIVE MARKET
10.4 AI TECHNOLOGIES
10.4.1 HARNESSING AI FOR IMPROVED PATIENT OUTCOMES AND OPERATIONAL EFFICIENCY TO SUPPORT MARKET GROWTH
10.5 SERVICES
10.5.1 INCREASING FOCUS ON SEAMLESS AI DEPLOYMENT AND ONGOING SUPPORT TO FACILITATE SEGMENTAL GROWTH
11 AI IN HEALTHCARE MARKET, BY APPLICATION
11.1 INTRODUCTION
11.2 CLINICAL APPLICATIONS
11.2.1 NECESSITY TO ENHANCE PATIENT MONITORING AND CLINICAL DECISION-MAKING ABILITY TO SPUR DEMAND
11.3 NON-CLINICAL APPLICATIONS
11.3.1 REQUIREMENT TO ENHANCE OPERATIONAL EFFICIENCY, REDUCE ADMINISTRATIVE BURDEN, AND ENSURE BETTER RESOURCE ALLOCATION TO FOSTER MARKET GROWTH
12 AI IN HEALTHCARE MARKET, BY DEPLOYMENT MODEL
12.1 INTRODUCTION
12.2 ON-PREMISES MODEL
12.2.1 CRITICALITY OF DATA PRIVACY AND SECURITY TO SUPPORT DEPLOYMENT OF ON-PREMISES HEALTHCARE INFRASTRUCTURE
12.3 CLOUD-BASED MODEL
12.3.1 RAPID SCALABILITY AND SECURE DATA HANDLING AND INTEGRATION ATTRIBUTES TO ELEVATE DEMAND FOR CLOUD-BASED AI SOLUTIONS IN HEALTHCARE
12.4 HYBRID MODEL
12.4.1 FOCUS OF HEALTHCARE ORGANIZATIONS ON PROTECTING DATA WITHOUT SACRIFICING SCALABILITY TO DRIVE SEGMENTAL GROWTH
13 AI IN HEALTHCARE MARKET, BY TOOL
13.1 INTRODUCTION
13.2 MACHINE LEARNING
13.2.1 DEEP LEARNING
13.2.1.1 Convolutional neural networks
13.2.1.1.1 Ability to analyze X-rays, CT scans, and MRIs with high precision to elevate adoption
13.2.1.2 Recurrent neural networks
13.2.1.2.1 Competency in analyzing sequential data to predict disease progression and treatment efficacy to boost deployment
13.2.1.3 Generative adversarial networks
13.2.1.3.1 Capability to generate synthetic data to train AI models and address data scarcity and privacy issues to propel demand
13.2.1.4 Graph neural networks
13.2.1.4.1 Ability to recommend personalized treatment to stimulate adoption
13.2.1.5 Other deep learning tools
13.2.2 SUPERVISED LEARNING
13.2.2.1 Growing importance of evidence-based decision-making in predictive and diagnostic tasks to spur demand
13.2.3 REINFORCEMENT LEARNING
13.2.3.1 Significance of precision medicine, value-based care, and intelligent clinical decision support to accelerate demand
13.2.4 UNSUPERVISED LEARNING
13.2.4.1 Increasing need to uncover hidden insights from unstructured healthcare data to boost adoption
13.2.5 OTHER MACHINE LEARNING TOOLS
13.3 NATURAL LANGUAGE PROCESSING
13.3.1 SENTIMENT ANALYSIS
13.3.1.1 Increasing adoption of AI for patient feedback analysis to contribute to market growth
13.3.2 PATTERN & IMAGE RECOGNITION
13.3.2.1 Growing utilization of AI for early disease detection and personalized treatment planning to facilitate market expansion
13.3.3 AUTO CODING
13.3.3.1 Elevating use of AI tools to improve claim reimbursement process to fuel market growth
13.3.4 CLASSIFICATION & CATEGORIZATION
13.3.4.1 Business need to organize and classify healthcare data efficiently to expand AI implementation
13.3.5 TEXT ANALYTICS
13.3.5.1 Necessity to derive insights from unstructured clinical text to enhance use of text analytics
13.3.6 SPEECH RECOGNITION
13.3.6.1 Rising focus on reducing physician administrative burden to accelerate demand
13.4 CONTEXT-AWARE COMPUTING
13.4.1 DEVICE CONTEXT
13.4.1.1 Integration of connected medical devices to boost demand for intelligent device-aware healthcare applications
13.4.2 USER CONTEXT
13.4.2.1 Rising focus on individualized clinical decision support to spike demand
13.4.3 PHYSICAL CONTEXT
13.4.3.1 Increasing adoption of AI for real-time environmental and patient context monitoring to generate demand
13.5 GENERATIVE AI
13.5.1 INCREASING USE OF GENERATIVE MODELS TO OFFER TAILORED INTERVENTIONS TO DRIVE MARKET
13.6 COMPUTER VISION
13.6.1 ABILITY TO DETECT ABNORMALITIES SUCH AS TUMORS AND FRACTURES TO FUEL ADOPTION
13.7 IMAGE ANALYSIS
13.7.1 GROWING ADOPTION OF AI FOR EARLY DISEASE DETECTION AND DIAGNOSIS TO CONTRIBUTE TO MARKT GROWTH
14 AI IN HEALTHCARE MARKET, BY END USER
14.1 INTRODUCTION
14.2 HEALTHCARE PROVIDERS
14.2.1 HOSPITALS & CLINICS
14.2.1.1 Increasing focus on enhancing patient outcomes through AI to expedite market expansion
14.2.2 AMBULATORY CARE CENTERS
14.2.2.1 Rising adoption of AI to reduce care delivery costs to reinforce market growth
14.2.3 HOME HEALTHCARE AGENCIES & ASSISTED-LIVING FACILITIES
14.2.3.1 Escalating demand for personalized and continuous patient care to accelerate market growth
14.2.4 DIAGNOSTIC & IMAGING CENTERS
14.2.4.1 Increasing partnerships between hospitals and imaging centers to develop regulatory-cleared AI tools to support market growth
14.2.5 PHARMACIES
14.2.5.1 Heightened need for AI-driven inventory optimization to unlock opportunities
14.2.6 OTHER HEALTHCARE PROVIDERS
14.3 HEALTHCARE PAYERS
14.3.1 PUBLIC PAYERS
14.3.1.1 Increasing focus on cost optimization and fraud prevention to promote adoption of AI by public payers
14.3.2 PRIVATE PAYERS
14.3.2.1 Leveraging AI to optimize claims management, member engagement, and value-based care programs to drive market
14.4 PATIENTS
14.4.1 INCREASING ADOPTION OF AI FOR PATIENT ENGAGEMENT AND SELF-CARE TO FACILITATE MARKET GROWTH
14.5 OTHER END USERS
15 AI IN HEALTHCARE MARKET, BY REGION
15.1 INTRODUCTION
15.2 NORTH AMERICA
15.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
15.2.2 US
15.2.2.1 Increasing focus on personalized medicine and precision healthcare to drive market
15.2.3 CANADA
15.2.3.1 Rising use of AI to improve disease care and patient survival and clinical workflows to drive market
15.3 EUROPE
15.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
15.3.2 GERMANY
15.3.2.1 Collaborative health-related research and innovation programs and initiatives to contribute to market growth
15.3.3 UK
15.3.3.1 Significant focus of government on early diagnosis, personalized treatments, and rapid drug development to boost AI demand
15.3.4 FRANCE
15.3.4.1 Expanding AI-enabled digital healthcare and patient services to foster market growth
15.3.5 ITALY
15.3.5.1 Growing deployment of AI infrastructure to ensure transparency, data protection, and patient safety to facilitate market growth
15.3.6 SPAIN
15.3.6.1 Partnerships between scientists, medical professionals, and AI experts to develop innovative diagnostic tools to drive market
15.3.7 REST OF EUROPE
15.4 ASIA PACIFIC
15.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
15.4.2 CHINA
15.4.2.1 Growing focus on healthcare innovation through national AI initiatives to accelerate market growth
15.4.3 JAPAN
15.4.3.1 Strong healthcare infrastructure to drive adoption of advanced AI
15.4.4 INDIA
15.4.4.1 Strong government support for digital health initiatives to create lucrative opportunities
15.4.5 AUSTRALIA
15.4.5.1 Strong research ecosystem and national digital health initiatives to drive market
15.4.6 SOUTH KOREA
15.4.6.1 National Strategy for Artificial Intelligence and Digital Healthcare Innovation Plan initiatives to support market growth
15.4.7 REST OF ASIA PACIFIC
15.5 LATIN AMERICA
15.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
15.5.2 BRAZIL
15.5.2.1 Expanding digital health infrastructure and growing adoption of AI-enabled healthcare technologies to foster market growth
15.5.3 MEXICO
15.5.3.1 Growing adoption of AI-driven chronic disease management platforms to stimulate market growth
15.5.4 REST OF LATIN AMERICA
15.6 MIDDLE EAST & AFRICA
15.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
15.6.2 GCC
15.6.2.1 Saudi Arabia
15.6.2.1.1 Accelerating AI-driven healthcare transformation under Saudi Vision 2030 to contribute to market growth
15.6.2.2 UAE
15.6.2.2.1 Rising focus on improving healthcare quality and delivering personalized patient care to reinforce market growth
15.6.2.3 Rest of GCC
15.6.3 SOUTH AFRICA
15.6.3.1 Expanding use of AI to enhance medical imaging, clinical decision support, and disease surveillance to drive market
15.6.4 REST OF MIDDLE EAST & AFRICA
16 COMPETITIVE LANDSCAPE
16.1 INTRODUCTION
16.2 KEY PLAYER COMPETITIVE STRATEGY/RIGHT TO WIN, JANUARY 2023 TO JUNE 2026
16.3 REVENUE ANALYSIS, 2021–2025
16.4 MARKET SHARE ANALYSIS, 2025
16.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
16.5.1 STARS
16.5.2 EMERGING LEADERS
16.5.3 PERVASIVE PLAYERS
16.5.4 PARTICIPANTS
16.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
16.5.5.1 Company footprint
16.5.5.2 Region footprint
16.5.5.3 Application footprint
16.5.5.4 Tool footprint
16.5.5.5 Function footprint
16.5.5.6 Offering footprint
16.5.5.7 Deployment footprint
16.5.5.8 End user footprint
16.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
16.6.1 PROGRESSIVE COMPANIES
16.6.2 RESPONSIVE COMPANIES
16.6.3 DYNAMIC COMPANIES
16.6.4 STARTING BLOCKS
16.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
16.6.5.1 Detailed list of key startups/SMEs
16.6.5.2 Company footprint (startups/SMEs)
16.7 COMPANY VALUATION AND FINANCIAL METRICS
16.7.1 FINANCIAL METRICS
16.7.2 COMPANY VALUATION
16.8 BRAND/PRODUCT COMPARISON
16.9 COMPETITIVE SCENARIO
16.9.1 PRODUCT LAUNCHES/ENHANCEMENTS/APPROVALS
16.9.2 DEALS
16.9.3 OTHER DEVELOPMENTS
17 COMPANY PROFILES
17.1 KEY PLAYERS
17.1.1 KONINKLIJKE PHILIPS N.V.
17.1.1.1 Business overview
17.1.1.2 Products & services offered
17.1.1.3 Recent developments
17.1.1.3.1 Product launches/enhancements/approvals
17.1.1.3.2 Deals
17.1.1.3.3 Expansions
17.1.1.3.4 Other developments
17.1.1.4 MnM view
17.1.1.4.1 Right to win
17.1.1.4.2 Strategic choices
17.1.1.4.3 Weaknesses & competitive threats
17.1.2 MICROSOFT CORPORATION
17.1.2.1 Business overview
17.1.2.2 Products & services offered
17.1.2.3 Recent developments
17.1.2.3.1 Product launches/enhancements/approvals
17.1.2.3.2 Deals
17.1.2.4 MnM view
17.1.2.4.1 Right to win
17.1.2.4.2 Strategic choices
17.1.2.4.3 Weaknesses & competitive threats
17.1.3 NVIDIA CORPORATION
17.1.3.1 Business overview
17.1.3.2 Products & services offered
17.1.3.3 Recent developments
17.1.3.3.1 Product launches/enhancements/approvals
17.1.3.3.2 Deals
17.1.3.4 MnM view
17.1.3.4.1 Right to win
17.1.3.4.2 Strategic choices
17.1.3.4.3 Weaknesses & competitive threats
17.1.4 SIEMENS HEALTHINEERS AG
17.1.4.1 Business overview
17.1.4.2 Products & services offered
17.1.4.3 Recent developments
17.1.4.3.1 Product launches/enhancements/approvals
17.1.4.3.2 Deals
17.1.4.4 MnM view
17.1.4.4.1 Right to win
17.1.4.4.2 Strategic choices
17.1.4.4.3 Weaknesses & competitive threats
17.1.5 GE HEALTHCARE
17.1.5.1 Business overview
17.1.5.2 Products & services offered
17.1.5.3 Recent developments
17.1.5.3.1 Product launches/enhancements/approvals
17.1.5.3.2 Deals
17.1.5.3.3 Other developments
17.1.5.4 MnM view
17.1.5.4.1 Right to win
17.1.5.4.2 Strategic choices
17.1.5.4.3 Weaknesses & competitive threats
17.1.6 EPIC SYSTEMS CORPORATION
17.1.6.1 Business overview
17.1.6.2 Products & services offered
17.1.6.3 Recent developments
17.1.6.3.1 Product launches/enhancements/approvals
17.1.6.3.2 Deals
17.1.7 ORACLE
17.1.7.1 Business overview
17.1.7.2 Products & services offered
17.1.7.3 Recent developments
17.1.7.3.1 Product launches/enhancements/approvals
17.1.7.3.2 Deals
17.1.7.3.3 Expansions
17.1.8 VERADIGM INC.
17.1.8.1 Business overview
17.1.8.2 Products & services offered
17.1.8.3 Recent developments
17.1.8.3.1 Product launches/enhancements/approvals
17.1.8.3.2 Deals
17.1.9 AMAZON WEB SERVICES, INC.
17.1.9.1 Business overview
17.1.9.2 Products & services offered
17.1.9.3 Recent developments
17.1.9.3.1 Product launches/enhancements/approvals
17.1.9.3.2 Deals
17.1.9.3.3 Expansions
17.1.10 MERATIVE
17.1.10.1 Business overview
17.1.10.2 Products & services offered
17.1.10.3 Recent developments
17.1.10.3.1 Product launches/enhancements/approvals
17.1.10.3.2 Deals
17.1.11 IBM
17.1.11.1 Business overview
17.1.11.2 Products & services offered
17.1.11.3 Recent developments
17.1.11.3.1 Deals
17.1.12 MEDTRONIC
17.1.12.1 Business overview
17.1.12.2 Products & services offered
17.1.12.3 Recent developments
17.1.12.3.1 Product launches/enhancements/approvals
17.1.12.3.2 Deals
17.1.13 GOOGLE
17.1.13.1 Business overview
17.1.13.2 Products & services offered
17.1.13.3 Recent developments
17.1.13.3.1 Product launches/enhancements/approvals
17.1.13.3.2 Deals
17.1.13.3.3 Other developments
17.1.14 SOPHIA GENETICS
17.1.14.1 Business overview
17.1.14.2 Products & services offered
17.1.14.3 Recent developments
17.1.14.3.1 Product launches/enhancements/approvals
17.1.14.3.2 Deals
17.1.14.3.3 Other developments
17.1.15 JOHNSON & JOHNSON SERVICES, INC.
17.1.15.1 Business overview
17.1.15.2 Products & services offered
17.1.15.3 Recent developments
17.1.15.3.1 Product launches/enhancements/approvals
17.1.15.3.2 Deals
17.1.16 TEMPUS AI, INC.
17.1.16.1 Business overview
17.1.16.2 Products & services offered
17.1.16.3 Recent developments
17.1.16.3.1 Product launches/enhancements/approvals
17.1.16.3.2 Deals
17.1.17 CONCERTAI
17.1.17.1 Business overview
17.1.17.2 Products & services offered
17.1.17.3 Recent developments
17.1.17.3.1 Product launches/enhancements/approvals
17.1.17.3.2 Deals
17.1.18 SOLVENTUM CORPORATION
17.1.18.1 Business overview
17.1.18.2 Products & services offered
17.1.18.3 Recent developments
17.1.18.3.1 Deals
17.1.18.3.2 Other developments
17.1.19 COGNIZANT
17.1.19.1 Business overview
17.1.19.2 Products & services offered
17.1.19.3 Recent developments
17.1.19.3.1 Product launches/enhancements/approvals
17.1.19.3.2 Deals
17.1.20 VIZ.AI, INC.
17.1.20.1 Business overview
17.1.20.2 Products & services offered
17.1.20.3 Recent developments
17.1.20.3.1 Product launches/enhancements/approvals
17.1.20.3.2 Deals
17.1.20.3.3 Other developments
17.1.21 RIVERAIN TECHNOLOGIES
17.1.21.1 Business overview
17.1.21.2 Products & services offered
17.1.21.3 Recent developments
17.1.21.3.1 Product launches/enhancements/approvals
17.1.21.3.2 Deals
17.2 OTHER PLAYERS
17.2.1 QVENTUS
17.2.2 QURE.AI
17.2.3 SUKI AI, INC.
17.2.4 ENLITIC
17.2.5 SEGMED
18 RESEARCH METHODOLOGY
18.1 RESEARCH DATA
18.1.1 SECONDARY DATA
18.1.1.1 Key data from secondary sources
18.1.2 PRIMARY DATA
18.1.2.1 Key data from primary sources
18.1.2.2 Key industry insights
18.2 MARKET SIZE ESTIMATION
18.3 DATA TRIANGULATION
18.4 MARKET SHARE ESTIMATION
18.5 RESEARCH ASSUMPTIONS
18.6 RESEARCH LIMITATIONS
18.6.1 METHODOLOGY-RELATED LIMITATIONS
18.6.2 SCOPE-RELATED LIMITATIONS
18.7 RISK ASSESSMENT
19 APPENDIX
19.1 DISCUSSION GUIDE
19.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
19.3 CUSTOMIZATION OPTIONS
19.4 RELATED REPORTS
19.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
2 EXECUTIVE SUMMARY
2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS IN AI IN HEALTHCARE MARKET
2.4 HIGH-GROWTH SEGMENTS
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
3.1 AI IN HEALTHCARE MARKET OVERVIEW
3.2 AI IN HEALTHCARE MARKET, BY APPLICATION AND REGION
3.3 AI IN HEALTHCARE MARKET: GEOGRAPHIC SNAPSHOT
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Increasing need for early detection and diagnosis of diseases
4.2.1.2 Exponential growth in data volume and complexity due to surging adoption of digital technologies
4.2.1.3 Significant cost pressure on healthcare service providers with increasing prevalence of chronic diseases
4.2.1.4 Rapid proliferation of AI in healthcare sector
4.2.1.5 Growing inclination toward precision medicine and personalized care
4.2.2 RESTRAINTS
4.2.2.1 Reluctance among medical practitioners to adopt AI-based technologies
4.2.2.2 Shortage of skilled AI professionals handling AI-powered solutions
4.2.2.3 Lack of standardized frameworks for AI and ML technologies
4.2.3 OPPORTUNITIES
4.2.3.1 Rising demand for AI-driven clinical decision support systems
4.2.3.2 Increasing focus on developing human-aware AI systems
4.2.3.3 Strategic partnerships and collaborations among healthcare companies and AI technology providers
4.2.3.4 Rising adoption of AI-enabled medical imaging and diagnostics
4.2.4 CHALLENGES
4.2.4.1 Inaccurate predictions due to scarcity of high-quality healthcare data
4.2.4.2 Concerns regarding data privacy
4.2.4.3 Lack of interoperability between AI solutions offered by different vendors
4.3 UNMET NEEDS AND WHITE SPACES
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
5 INDUSTRY TRENDS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 THREAT OF NEW ENTRANTS
5.1.2 THREAT OF SUBSTITUTES
5.1.3 BARGAINING POWER OF SUPPLIERS
5.1.4 BARGAINING POWER OF BUYERS
5.1.5 INTENSITY OF COMPETITIVE RIVALRY
5.2 MACROECONOMIC OUTLOOK
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS AND FORECAST
5.2.3 TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY
5.3 VALUE CHAIN ANALYSIS
5.4 ECOSYSTEM ANALYSIS
5.5 PRICING ANALYSIS
5.5.1 INDICATIVE PRICING FOR AI IN HEALTHCARE, BY APPLICATION (2025)
5.5.2 INDICATIVE PRICING FOR AI IN HEALTHCARE MARKET, BY REGION (2025)
5.6 KEY CONFERENCES AND EVENTS, 2026–2027
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.8 INVESTMENT AND FUNDING SCENARIO
5.9 CASE STUDY ANALYSIS
5.9.1 ACCELERATING LUNG CANCER DIAGNOSIS THROUGH AI ACROSS NHS HOSPITALS
5.9.2 STRENGTHENING PATIENT TRUST THROUGH DIGITAL PATIENT ENGAGEMENT SOLUTIONS
5.9.3 OPTIMIZING PATIENT ENGAGEMENT AND COMMUNICATION WITH TRUBRIDGE PATIENT CONNECT
5.10 IMPACT OF US TARIFF – OVERVIEW
5.10.1 INTRODUCTION
5.10.2 KEY TARIFF RATES
5.10.3 PRICE IMPACT ANALYSIS
5.10.4 IMPACT ON COUNTRIES/REGIONS
5.10.4.1 US
5.10.4.2 Europe
5.10.4.3 Asia Pacific
5.10.5 IMPACT ON END USERS
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1 KEY EMERGING TECHNOLOGIES
6.1.1 MACHINE LEARNING AND DEEP LEARNING
6.1.2 NATURAL LANGUAGE PROCESSING
6.1.3 COMPUTER VISION
6.2 COMPLEMENTARY TECHNOLOGIES
6.2.1 CLOUD COMPUTING
6.2.2 DIGITAL TWINS
6.2.3 ROBOTIC PROCESS AUTOMATION
6.3 ADJACENT TECHNOLOGIES
6.3.1 BLOCKCHAIN
6.3.2 AUGMENTED REALITY AND VIRTUAL REALITY
6.3.3 INTERNET OF THINGS
6.4 PATENT ANALYSIS
6.4.1 PATENT PUBLICATION TRENDS FOR AI IN HEALTHCARE LANDSCAPE
6.4.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
6.5 FUTURE APPLICATIONS
6.5.1 AI-DRIVEN PRECISION MEDICINE
6.5.2 REAL-TIME CLINICAL DECISION SUPPORT WITH GENERATIVE AI
6.5.3 DISEASE PREDICTION AND EARLY INTERVENTION THROUGH PREDICTIVE ANALYTICS
6.5.4 AI-POWERED VIRTUAL HEALTH ASSISTANTS AND DIGITAL CARE NAVIGATION
6.5.5 ADVANCING AUTONOMOUS AI AGENTS FOR HEALTHCARE WORKFLOW AUTOMATION
7 REGULATORY LANDSCAPE
7.1 REGIONAL REGULATIONS AND COMPLIANCE
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2 REGULATORY FRAMEWORK
8 CUSTOMER LANDSCAPE AND BUYER BEHAVIOR
8.1 INTRODUCTION
8.2 DECISION-MAKING PROCESS
8.3 KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR EVALUATION CRITERIA
8.3.1 KEY STAKEHOLDERS IN BUYING PROCESS
8.3.2 BUYING CRITERIA
8.4 ADOPTION BARRIERS AND INTERNAL CHALLENGES
8.5 UNMET NEEDS OF VARIOUS END USERS
8.5.1 UNMET NEEDS
8.5.2 END-USER EXPECTATIONS
8.6 MARKET PROFITABILITY
8.7 IMPACT ON COUNTRIES/REGIONS
8.7.1 US
8.7.2 EUROPE
8.7.3 ASIA PACIFIC
8.8 IMPACT ON END USERS
9 AI IN HEALTHCARE MARKET, BY FUNCTION
9.1 INTRODUCTION
9.2 DIAGNOSIS & EARLY DETECTION
9.2.1 PRE-SCREENING
9.2.1.1 Early detection, better outcomes, and cost-effective care associated with pre-screening to boost market
9.2.2 IVD
9.2.2.1 IVD market, by technology
9.2.2.1.1 Immunoassays
9.2.2.1.1.1 Potential to enhance biomarker detection and laboratory automation to accelerate demand
9.2.2.1.2 Clinical chemistry
9.2.2.1.2.1 Ability to improve laboratory efficiency and diagnostic accuracy to spur adoption
9.2.2.1.3 Molecular diagnostics
9.2.2.1.3.1 Pressing need to identify viral and bacterial pathogens in infectious diseases to facilitate adoption
9.2.2.2 IVD market, by application
9.2.2.2.1 Image analysis & interpretation
9.2.2.2.1.1 Rising focus of pathologists on analyzing tissue samples for detecting abnormalities at faster rate to fuel segmental growth
9.2.2.2.2 Biomarker discovery & analysis
9.2.2.2.2.1 Elevating adoption of precision medicine to create growth opportunities
9.2.2.2.3 Other IVD applications
9.2.3 DIAGNOSTIC IMAGING
9.2.3.1 Diagnostic imaging market, by application
9.2.3.1.1 Disease interpretation & report analysis
9.2.3.1.1.1 Proficiency in identifying disease-specific patterns and correlating findings across multiple data sources to fuel adoption
9.2.3.1.2 Image captioning & annotation
9.2.3.1.2.1 Increasing use of machine learning for automated image captioning to foster market growth
9.2.3.1.3 Image reconstruction
9.2.3.1.3.1 Greater emphasis of healthcare facilities on optimizing imaging workflows and increasing scanner throughput to augment adoption
9.2.3.1.4 Other diagnostic imaging applications
9.2.3.2 Diagnostic imaging market, by modality
9.2.3.2.1 Magnetic resonance imaging
9.2.3.2.1.1 Escalating adoption of AI across MRI workflows to enhance diagnostic confidence and improve scanner utilization to augment market growth
9.2.3.2.2 Computed tomography
9.2.3.2.2.1 Urgent need for efficient diagnosis to provide the right treatments to drive market
9.2.3.2.3 X-ray imaging
9.2.3.2.3.1 Development of innovative AI-based X-ray imaging solutions to drive market
9.2.3.2.4 Ultrasound
9.2.3.2.4.1 Increasing investments in developing AI-assisted ultrasound imaging auto-assessment tools to expedite market growth
9.2.3.2.5 Nuclear imaging
9.2.3.2.5.1 Integration of AI algorithms for quick detection and monitoring of abnormalities to facilitate market growth
9.2.3.2.6 Other diagnostic imaging modalities
9.2.4 RISK ASSESSMENT & PATIENT STRATIFICATION
9.2.4.1 Critical need to identify high-risk patients and predict their disease progression risks to boost demand
9.2.5 DRUG ALLERGY ALERTING
9.2.5.1 Significant focus on improving accuracy and speed of identifying allergic reactions to contribute to market growth
9.2.6 OTHER DIAGNOSIS & EARLY DETECTION FUNCTIONS
9.3 TREATMENT PLANNING & PERSONALIZATION
9.3.1 PERSONALIZED TREATMENT PLANNING
9.3.1.1 Precision medicine & genomic analysis
9.3.1.1.1 Adoption of AI-based software for personalized treatment decisions and improved outcomes to propel market
9.3.1.2 Predictive models for treatment response
9.3.1.2.1 Ability to personalize therapies, improve outcomes, and minimize adverse effects to fuel growth
9.3.1.3 Treatment recommendation systems
9.3.1.3.1 Competency in offering personalized, evidence-based treatment options to spike demand
9.3.2 PHARMACOLOGICAL THERAPY
9.3.2.1 Drug response prediction
9.3.2.1.1 Increasing use of AI-powered drug response prediction in oncology and chronic disease management to drive market
9.3.2.2 Dosing & administration
9.3.2.2.1 Capability of AI-based dosing models to adjust doses in real-time based on individual patient responses to spur demand
9.3.2.3 Other pharmacological therapy functions
9.3.3 SURGICAL THERAPY
9.3.3.1 Preoperative imaging & 3D modeling
9.3.3.1.1 Widening use of AI-driven 3D modeling in orthopedic, cardiovascular, neurological surgeries to fuel market growth
9.3.3.2 Intraoperative guidance & robotics
9.3.3.2.1 Inclination toward minimally invasive surgeries and faster patient recovery to boost implementation
9.3.3.3 Postoperative analysis & recovery
9.3.3.3.1 Ability to predict recovery patterns, identify risks, and provide personalized rehabilitation plans to boost demand
9.3.4 RADIATION THERAPY
9.3.4.1 Motion synchronization & auto contouring
9.3.4.1.1 Need for precise delivery of radiation and minimum exposure to surrounding healthy tissues to reinforce segmental growth
9.3.4.2 Real-time adaptive treatment delivery
9.3.4.2.1 Growing focus on consistent treatment accuracy and clinical outcome optimization to strengthen demand
9.3.4.3 Response assessment & quality assurance
9.3.4.3.1 Ability of AI solutions to analyze medical images, treatment plans, and dosimetric data to accelerate demand
9.3.4.4 Other radiation therapy functions
9.3.5 BEHAVIORAL THERAPY & PSYCHOTHERAPY
9.3.5.1 Virtual counseling & chatbots
9.3.5.1.1 Potential to improve patient communication, engagement, and service efficiency to expand implementation
9.3.5.2 Progress monitoring & feedback
9.3.5.2.1 Increasing use of smart wearables and mobile health apps to drive market
9.3.5.3 Follow-up & long-term support
9.3.5.3.1 Widespread adoption of telemedicine platforms to drive market expansion
9.3.6 IMMUNOTHERAPY
9.3.6.1 Real-time patient data monitoring
9.3.6.1.1 High demand for proactive healthcare management to foster segmental growth
9.3.6.2 Response & side-effect prediction
9.3.6.2.1 Need for earlier detection of treatment-related risks across drugs and vaccines to support segmental growth
9.3.6.3 Relapse prediction & long-term management
9.3.6.3.1 Necessity for continuous patient monitoring and risk stratification to fuel demand
9.3.7 OTHER TREATMENT PLANNING & PERSONALIZATION FUNCTIONS
9.4 PATIENT ENGAGEMENT & REMOTE MONITORING
9.4.1 SYMPTOM MANAGEMENT & VIRTUAL ASSISTANCE
9.4.1.1 Constant requirement for symptom management in chronic diseases to accelerate adoption of AI-powered apps
9.4.2 TELEHEALTH & REMOTE PATIENT MONITORING
9.4.2.1 Increasing adoption of mobile health apps and wearable devices to augment segmental growth
9.4.3 HEALTHCARE ASSISTANCE ROBOTS
9.4.3.1 Competency in improving quality of care and reducing burden on healthcare workers to promote adoption
9.4.4 MEDICATION REMINDERS
9.4.4.1 Capability to deliver medication guidance, personalized health coaching, and care coordination to foster demand
9.4.5 PATIENT EDUCATION & EMPOWERMENT
9.4.5.1 Need to improve treatment adherence and enhance self-management to drive market
9.4.6 OTHER PATIENT ENGAGEMENT & REMOTE MONITORING FUNCTIONS
9.5 POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE
9.5.1 RECURRENCE MONITORING
9.5.1.1 Advancing post-treatment care through intelligent recurrence monitoring to support market growth
9.5.2 LONG-TERM OUTCOME PREDICTION
9.5.2.1 Greater emphasis on predicting disease recurrence and survival chances to improve uptake of AI-powered medical devices
9.5.3 MENTAL HEALTH & SUPPORT SYSTEMS
9.5.3.1 Rising focus on emotional well-being of patients with critical illness to support segmental growth
9.6 PHARMACY MANAGEMENT
9.6.1 EPRESCRIBING
9.6.1.1 Urgent need to replace paper-based prescription to electronic platform to expedite adoption of ePrescribing solutions
9.6.2 MEDICATION MANAGEMENT
9.6.2.1 Innovative medication management programs between healthcare professionals and pharmacists to encourage segmental growth
9.6.3 PHARMACY AUDIT & ANALYSIS
9.6.3.1 Demand for operational excellence and improved patient care outcomes across pharmacies to create growth opportunities
9.6.4 OTHER PHARMACY MANAGEMENT FUNCTIONS
9.7 DATA MANAGEMENT & ANALYTICS
9.7.1 RISING FOCUS OF HEALTHCARE ORGANIZATIONS ON DEVELOPING PERSONALIZED TREATMENT PLANS TO SUPPORT SEGMENTAL GROWTH
9.8 AI SCRIBE
9.8.1 GROWING NEED TO IMPROVE CLINICIAN PRODUCTIVITY AND REDUCE DOCUMENTATION TIME TO STRENGTHEN AI SCRIBE DEPLOYMENT
9.9 CLINICAL DECISION SUPPORT SYSTEMS
9.9.1 INCREASING NEED FOR EVIDENCE-BASED CLINICAL DECISION-MAKING TO SPIKE ADOPTION
9.10 ADMINISTRATIVE
9.10.1 PATIENT REGISTRATION & SCHEDULING
9.10.1.1 Rising adoption of self-service patient registration solutions to contribute to segmental growth
9.10.2 PATIENT ELIGIBILITY & AUTHORIZATION
9.10.2.1 Growing demand for faster prior authorization workflows to facilitate market growth
9.10.3 REVENUE CYCLE MANAGEMENT
9.10.3.1 Significant need to reduce claim denials and reimbursement delays to reinforce demand
9.10.4 WORKFORCE MANAGEMENT
9.10.4.1 Growing need to optimize healthcare workforce utilization to create lucrative opportunities
9.10.5 SUPPLY CHAIN & INVENTORY MANAGEMENT
9.10.5.1 Strong focus on reducing inventory costs and waste to bolster market growth
9.10.6 COMPLIANCE & DOCUMENTATION
9.10.6.1 Increasing regulatory compliance requirements in healthcare to escalate demand for AI-based compliance & documentation
9.10.7 HEALTHCARE WORKFLOW MANAGEMENT
9.10.7.1 Surging need for end-to-end workflow automation to foster segmental growth
9.10.8 ASSET MANAGEMENT
9.10.8.1 Pressing need to improve equipment availability and reduce downtime to heighten demand for AI-based asset management
9.10.9 CUSTOMER RELATIONSHIP MANAGEMENT
9.10.9.1 Growing focus on personalized patient engagement to boost segmental growth
9.10.10 FRAUD DETECTION & RISK MANAGEMENT
9.10.10.1 Rising financial losses to drive investment in AI-based proactive risk management solutions
9.10.11 CYBERSECURITY
9.10.11.1 Critical requirement to protect sensitive patient data to propel demand for AI-powered threat detection solutions
9.10.12 OTHER ADMINISTRATIVE FUNCTIONS
10 AI IN HEALTHCARE MARKET, BY OFFERING
10.1 INTRODUCTION
10.2 INTEGRATED SOLUTIONS
10.2.1 ESCALATING DEPLOYMENT OF ENTERPRISE-WIDE AI PLATFORMS TO CONTRIBUTE TO SEGMENTAL GROWTH
10.3 NICHE/POINT SOLUTIONS
10.3.1 GROWING ADOPTION OF SPECIALIZED AI APPLICATIONS FOR TARGETED CLINICAL AND ADMINISTRATIVE TASKS TO DRIVE MARKET
10.4 AI TECHNOLOGIES
10.4.1 HARNESSING AI FOR IMPROVED PATIENT OUTCOMES AND OPERATIONAL EFFICIENCY TO SUPPORT MARKET GROWTH
10.5 SERVICES
10.5.1 INCREASING FOCUS ON SEAMLESS AI DEPLOYMENT AND ONGOING SUPPORT TO FACILITATE SEGMENTAL GROWTH
11 AI IN HEALTHCARE MARKET, BY APPLICATION
11.1 INTRODUCTION
11.2 CLINICAL APPLICATIONS
11.2.1 NECESSITY TO ENHANCE PATIENT MONITORING AND CLINICAL DECISION-MAKING ABILITY TO SPUR DEMAND
11.3 NON-CLINICAL APPLICATIONS
11.3.1 REQUIREMENT TO ENHANCE OPERATIONAL EFFICIENCY, REDUCE ADMINISTRATIVE BURDEN, AND ENSURE BETTER RESOURCE ALLOCATION TO FOSTER MARKET GROWTH
12 AI IN HEALTHCARE MARKET, BY DEPLOYMENT MODEL
12.1 INTRODUCTION
12.2 ON-PREMISES MODEL
12.2.1 CRITICALITY OF DATA PRIVACY AND SECURITY TO SUPPORT DEPLOYMENT OF ON-PREMISES HEALTHCARE INFRASTRUCTURE
12.3 CLOUD-BASED MODEL
12.3.1 RAPID SCALABILITY AND SECURE DATA HANDLING AND INTEGRATION ATTRIBUTES TO ELEVATE DEMAND FOR CLOUD-BASED AI SOLUTIONS IN HEALTHCARE
12.4 HYBRID MODEL
12.4.1 FOCUS OF HEALTHCARE ORGANIZATIONS ON PROTECTING DATA WITHOUT SACRIFICING SCALABILITY TO DRIVE SEGMENTAL GROWTH
13 AI IN HEALTHCARE MARKET, BY TOOL
13.1 INTRODUCTION
13.2 MACHINE LEARNING
13.2.1 DEEP LEARNING
13.2.1.1 Convolutional neural networks
13.2.1.1.1 Ability to analyze X-rays, CT scans, and MRIs with high precision to elevate adoption
13.2.1.2 Recurrent neural networks
13.2.1.2.1 Competency in analyzing sequential data to predict disease progression and treatment efficacy to boost deployment
13.2.1.3 Generative adversarial networks
13.2.1.3.1 Capability to generate synthetic data to train AI models and address data scarcity and privacy issues to propel demand
13.2.1.4 Graph neural networks
13.2.1.4.1 Ability to recommend personalized treatment to stimulate adoption
13.2.1.5 Other deep learning tools
13.2.2 SUPERVISED LEARNING
13.2.2.1 Growing importance of evidence-based decision-making in predictive and diagnostic tasks to spur demand
13.2.3 REINFORCEMENT LEARNING
13.2.3.1 Significance of precision medicine, value-based care, and intelligent clinical decision support to accelerate demand
13.2.4 UNSUPERVISED LEARNING
13.2.4.1 Increasing need to uncover hidden insights from unstructured healthcare data to boost adoption
13.2.5 OTHER MACHINE LEARNING TOOLS
13.3 NATURAL LANGUAGE PROCESSING
13.3.1 SENTIMENT ANALYSIS
13.3.1.1 Increasing adoption of AI for patient feedback analysis to contribute to market growth
13.3.2 PATTERN & IMAGE RECOGNITION
13.3.2.1 Growing utilization of AI for early disease detection and personalized treatment planning to facilitate market expansion
13.3.3 AUTO CODING
13.3.3.1 Elevating use of AI tools to improve claim reimbursement process to fuel market growth
13.3.4 CLASSIFICATION & CATEGORIZATION
13.3.4.1 Business need to organize and classify healthcare data efficiently to expand AI implementation
13.3.5 TEXT ANALYTICS
13.3.5.1 Necessity to derive insights from unstructured clinical text to enhance use of text analytics
13.3.6 SPEECH RECOGNITION
13.3.6.1 Rising focus on reducing physician administrative burden to accelerate demand
13.4 CONTEXT-AWARE COMPUTING
13.4.1 DEVICE CONTEXT
13.4.1.1 Integration of connected medical devices to boost demand for intelligent device-aware healthcare applications
13.4.2 USER CONTEXT
13.4.2.1 Rising focus on individualized clinical decision support to spike demand
13.4.3 PHYSICAL CONTEXT
13.4.3.1 Increasing adoption of AI for real-time environmental and patient context monitoring to generate demand
13.5 GENERATIVE AI
13.5.1 INCREASING USE OF GENERATIVE MODELS TO OFFER TAILORED INTERVENTIONS TO DRIVE MARKET
13.6 COMPUTER VISION
13.6.1 ABILITY TO DETECT ABNORMALITIES SUCH AS TUMORS AND FRACTURES TO FUEL ADOPTION
13.7 IMAGE ANALYSIS
13.7.1 GROWING ADOPTION OF AI FOR EARLY DISEASE DETECTION AND DIAGNOSIS TO CONTRIBUTE TO MARKT GROWTH
14 AI IN HEALTHCARE MARKET, BY END USER
14.1 INTRODUCTION
14.2 HEALTHCARE PROVIDERS
14.2.1 HOSPITALS & CLINICS
14.2.1.1 Increasing focus on enhancing patient outcomes through AI to expedite market expansion
14.2.2 AMBULATORY CARE CENTERS
14.2.2.1 Rising adoption of AI to reduce care delivery costs to reinforce market growth
14.2.3 HOME HEALTHCARE AGENCIES & ASSISTED-LIVING FACILITIES
14.2.3.1 Escalating demand for personalized and continuous patient care to accelerate market growth
14.2.4 DIAGNOSTIC & IMAGING CENTERS
14.2.4.1 Increasing partnerships between hospitals and imaging centers to develop regulatory-cleared AI tools to support market growth
14.2.5 PHARMACIES
14.2.5.1 Heightened need for AI-driven inventory optimization to unlock opportunities
14.2.6 OTHER HEALTHCARE PROVIDERS
14.3 HEALTHCARE PAYERS
14.3.1 PUBLIC PAYERS
14.3.1.1 Increasing focus on cost optimization and fraud prevention to promote adoption of AI by public payers
14.3.2 PRIVATE PAYERS
14.3.2.1 Leveraging AI to optimize claims management, member engagement, and value-based care programs to drive market
14.4 PATIENTS
14.4.1 INCREASING ADOPTION OF AI FOR PATIENT ENGAGEMENT AND SELF-CARE TO FACILITATE MARKET GROWTH
14.5 OTHER END USERS
15 AI IN HEALTHCARE MARKET, BY REGION
15.1 INTRODUCTION
15.2 NORTH AMERICA
15.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
15.2.2 US
15.2.2.1 Increasing focus on personalized medicine and precision healthcare to drive market
15.2.3 CANADA
15.2.3.1 Rising use of AI to improve disease care and patient survival and clinical workflows to drive market
15.3 EUROPE
15.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
15.3.2 GERMANY
15.3.2.1 Collaborative health-related research and innovation programs and initiatives to contribute to market growth
15.3.3 UK
15.3.3.1 Significant focus of government on early diagnosis, personalized treatments, and rapid drug development to boost AI demand
15.3.4 FRANCE
15.3.4.1 Expanding AI-enabled digital healthcare and patient services to foster market growth
15.3.5 ITALY
15.3.5.1 Growing deployment of AI infrastructure to ensure transparency, data protection, and patient safety to facilitate market growth
15.3.6 SPAIN
15.3.6.1 Partnerships between scientists, medical professionals, and AI experts to develop innovative diagnostic tools to drive market
15.3.7 REST OF EUROPE
15.4 ASIA PACIFIC
15.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
15.4.2 CHINA
15.4.2.1 Growing focus on healthcare innovation through national AI initiatives to accelerate market growth
15.4.3 JAPAN
15.4.3.1 Strong healthcare infrastructure to drive adoption of advanced AI
15.4.4 INDIA
15.4.4.1 Strong government support for digital health initiatives to create lucrative opportunities
15.4.5 AUSTRALIA
15.4.5.1 Strong research ecosystem and national digital health initiatives to drive market
15.4.6 SOUTH KOREA
15.4.6.1 National Strategy for Artificial Intelligence and Digital Healthcare Innovation Plan initiatives to support market growth
15.4.7 REST OF ASIA PACIFIC
15.5 LATIN AMERICA
15.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
15.5.2 BRAZIL
15.5.2.1 Expanding digital health infrastructure and growing adoption of AI-enabled healthcare technologies to foster market growth
15.5.3 MEXICO
15.5.3.1 Growing adoption of AI-driven chronic disease management platforms to stimulate market growth
15.5.4 REST OF LATIN AMERICA
15.6 MIDDLE EAST & AFRICA
15.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
15.6.2 GCC
15.6.2.1 Saudi Arabia
15.6.2.1.1 Accelerating AI-driven healthcare transformation under Saudi Vision 2030 to contribute to market growth
15.6.2.2 UAE
15.6.2.2.1 Rising focus on improving healthcare quality and delivering personalized patient care to reinforce market growth
15.6.2.3 Rest of GCC
15.6.3 SOUTH AFRICA
15.6.3.1 Expanding use of AI to enhance medical imaging, clinical decision support, and disease surveillance to drive market
15.6.4 REST OF MIDDLE EAST & AFRICA
16 COMPETITIVE LANDSCAPE
16.1 INTRODUCTION
16.2 KEY PLAYER COMPETITIVE STRATEGY/RIGHT TO WIN, JANUARY 2023 TO JUNE 2026
16.3 REVENUE ANALYSIS, 2021–2025
16.4 MARKET SHARE ANALYSIS, 2025
16.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
16.5.1 STARS
16.5.2 EMERGING LEADERS
16.5.3 PERVASIVE PLAYERS
16.5.4 PARTICIPANTS
16.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
16.5.5.1 Company footprint
16.5.5.2 Region footprint
16.5.5.3 Application footprint
16.5.5.4 Tool footprint
16.5.5.5 Function footprint
16.5.5.6 Offering footprint
16.5.5.7 Deployment footprint
16.5.5.8 End user footprint
16.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
16.6.1 PROGRESSIVE COMPANIES
16.6.2 RESPONSIVE COMPANIES
16.6.3 DYNAMIC COMPANIES
16.6.4 STARTING BLOCKS
16.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
16.6.5.1 Detailed list of key startups/SMEs
16.6.5.2 Company footprint (startups/SMEs)
16.7 COMPANY VALUATION AND FINANCIAL METRICS
16.7.1 FINANCIAL METRICS
16.7.2 COMPANY VALUATION
16.8 BRAND/PRODUCT COMPARISON
16.9 COMPETITIVE SCENARIO
16.9.1 PRODUCT LAUNCHES/ENHANCEMENTS/APPROVALS
16.9.2 DEALS
16.9.3 OTHER DEVELOPMENTS
17 COMPANY PROFILES
17.1 KEY PLAYERS
17.1.1 KONINKLIJKE PHILIPS N.V.
17.1.1.1 Business overview
17.1.1.2 Products & services offered
17.1.1.3 Recent developments
17.1.1.3.1 Product launches/enhancements/approvals
17.1.1.3.2 Deals
17.1.1.3.3 Expansions
17.1.1.3.4 Other developments
17.1.1.4 MnM view
17.1.1.4.1 Right to win
17.1.1.4.2 Strategic choices
17.1.1.4.3 Weaknesses & competitive threats
17.1.2 MICROSOFT CORPORATION
17.1.2.1 Business overview
17.1.2.2 Products & services offered
17.1.2.3 Recent developments
17.1.2.3.1 Product launches/enhancements/approvals
17.1.2.3.2 Deals
17.1.2.4 MnM view
17.1.2.4.1 Right to win
17.1.2.4.2 Strategic choices
17.1.2.4.3 Weaknesses & competitive threats
17.1.3 NVIDIA CORPORATION
17.1.3.1 Business overview
17.1.3.2 Products & services offered
17.1.3.3 Recent developments
17.1.3.3.1 Product launches/enhancements/approvals
17.1.3.3.2 Deals
17.1.3.4 MnM view
17.1.3.4.1 Right to win
17.1.3.4.2 Strategic choices
17.1.3.4.3 Weaknesses & competitive threats
17.1.4 SIEMENS HEALTHINEERS AG
17.1.4.1 Business overview
17.1.4.2 Products & services offered
17.1.4.3 Recent developments
17.1.4.3.1 Product launches/enhancements/approvals
17.1.4.3.2 Deals
17.1.4.4 MnM view
17.1.4.4.1 Right to win
17.1.4.4.2 Strategic choices
17.1.4.4.3 Weaknesses & competitive threats
17.1.5 GE HEALTHCARE
17.1.5.1 Business overview
17.1.5.2 Products & services offered
17.1.5.3 Recent developments
17.1.5.3.1 Product launches/enhancements/approvals
17.1.5.3.2 Deals
17.1.5.3.3 Other developments
17.1.5.4 MnM view
17.1.5.4.1 Right to win
17.1.5.4.2 Strategic choices
17.1.5.4.3 Weaknesses & competitive threats
17.1.6 EPIC SYSTEMS CORPORATION
17.1.6.1 Business overview
17.1.6.2 Products & services offered
17.1.6.3 Recent developments
17.1.6.3.1 Product launches/enhancements/approvals
17.1.6.3.2 Deals
17.1.7 ORACLE
17.1.7.1 Business overview
17.1.7.2 Products & services offered
17.1.7.3 Recent developments
17.1.7.3.1 Product launches/enhancements/approvals
17.1.7.3.2 Deals
17.1.7.3.3 Expansions
17.1.8 VERADIGM INC.
17.1.8.1 Business overview
17.1.8.2 Products & services offered
17.1.8.3 Recent developments
17.1.8.3.1 Product launches/enhancements/approvals
17.1.8.3.2 Deals
17.1.9 AMAZON WEB SERVICES, INC.
17.1.9.1 Business overview
17.1.9.2 Products & services offered
17.1.9.3 Recent developments
17.1.9.3.1 Product launches/enhancements/approvals
17.1.9.3.2 Deals
17.1.9.3.3 Expansions
17.1.10 MERATIVE
17.1.10.1 Business overview
17.1.10.2 Products & services offered
17.1.10.3 Recent developments
17.1.10.3.1 Product launches/enhancements/approvals
17.1.10.3.2 Deals
17.1.11 IBM
17.1.11.1 Business overview
17.1.11.2 Products & services offered
17.1.11.3 Recent developments
17.1.11.3.1 Deals
17.1.12 MEDTRONIC
17.1.12.1 Business overview
17.1.12.2 Products & services offered
17.1.12.3 Recent developments
17.1.12.3.1 Product launches/enhancements/approvals
17.1.12.3.2 Deals
17.1.13 GOOGLE
17.1.13.1 Business overview
17.1.13.2 Products & services offered
17.1.13.3 Recent developments
17.1.13.3.1 Product launches/enhancements/approvals
17.1.13.3.2 Deals
17.1.13.3.3 Other developments
17.1.14 SOPHIA GENETICS
17.1.14.1 Business overview
17.1.14.2 Products & services offered
17.1.14.3 Recent developments
17.1.14.3.1 Product launches/enhancements/approvals
17.1.14.3.2 Deals
17.1.14.3.3 Other developments
17.1.15 JOHNSON & JOHNSON SERVICES, INC.
17.1.15.1 Business overview
17.1.15.2 Products & services offered
17.1.15.3 Recent developments
17.1.15.3.1 Product launches/enhancements/approvals
17.1.15.3.2 Deals
17.1.16 TEMPUS AI, INC.
17.1.16.1 Business overview
17.1.16.2 Products & services offered
17.1.16.3 Recent developments
17.1.16.3.1 Product launches/enhancements/approvals
17.1.16.3.2 Deals
17.1.17 CONCERTAI
17.1.17.1 Business overview
17.1.17.2 Products & services offered
17.1.17.3 Recent developments
17.1.17.3.1 Product launches/enhancements/approvals
17.1.17.3.2 Deals
17.1.18 SOLVENTUM CORPORATION
17.1.18.1 Business overview
17.1.18.2 Products & services offered
17.1.18.3 Recent developments
17.1.18.3.1 Deals
17.1.18.3.2 Other developments
17.1.19 COGNIZANT
17.1.19.1 Business overview
17.1.19.2 Products & services offered
17.1.19.3 Recent developments
17.1.19.3.1 Product launches/enhancements/approvals
17.1.19.3.2 Deals
17.1.20 VIZ.AI, INC.
17.1.20.1 Business overview
17.1.20.2 Products & services offered
17.1.20.3 Recent developments
17.1.20.3.1 Product launches/enhancements/approvals
17.1.20.3.2 Deals
17.1.20.3.3 Other developments
17.1.21 RIVERAIN TECHNOLOGIES
17.1.21.1 Business overview
17.1.21.2 Products & services offered
17.1.21.3 Recent developments
17.1.21.3.1 Product launches/enhancements/approvals
17.1.21.3.2 Deals
17.2 OTHER PLAYERS
17.2.1 QVENTUS
17.2.2 QURE.AI
17.2.3 SUKI AI, INC.
17.2.4 ENLITIC
17.2.5 SEGMED
18 RESEARCH METHODOLOGY
18.1 RESEARCH DATA
18.1.1 SECONDARY DATA
18.1.1.1 Key data from secondary sources
18.1.2 PRIMARY DATA
18.1.2.1 Key data from primary sources
18.1.2.2 Key industry insights
18.2 MARKET SIZE ESTIMATION
18.3 DATA TRIANGULATION
18.4 MARKET SHARE ESTIMATION
18.5 RESEARCH ASSUMPTIONS
18.6 RESEARCH LIMITATIONS
18.6.1 METHODOLOGY-RELATED LIMITATIONS
18.6.2 SCOPE-RELATED LIMITATIONS
18.7 RISK ASSESSMENT
19 APPENDIX
19.1 DISCUSSION GUIDE
19.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
19.3 CUSTOMIZATION OPTIONS
19.4 RELATED REPORTS
19.5 AUTHOR DETAILS
LIST OF TABLES
TABLE 1 INCLUSIONS AND EXCLUSIONS
TABLE 2 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
TABLE 3 AI IN HEALTHCARE MARKET: IMPACT ANALYSIS
TABLE 4 ARTIFICIAL INTELLIGENCE IN HEALTHCARE MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 5 AI IN HEALTHCARE MARKET: ROLE IN ECOSYSTEM
TABLE 6 INDICATIVE PRICING FOR AI IN HEALTHCARE, BY NON-CLINICAL APPLICATION (2025)
TABLE 7 INDICATIVE PRICING FOR AI IN HEALTHCARE, BY CLINICAL APPLICATION (2025)
TABLE 8 CASE 1: AI-ENABLED LUNG CANCER DIAGNOSIS IN NHS HOSPITALS
TABLE 9 CASE 2: AI-DRIVEN PATIENT ENGAGEMENT IN CHILDREN'S HEALTHCARE
TABLE 10 CASE 3: DIGITAL PATIENT ENGAGEMENT AT SPARTA COMMUNITY HOSPITAL
TABLE 11 US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 12 EXPECTED CHANGE IN PRICES AND LIKELY IMPACT ON END-USE MARKET DUE TO TARIFF IMPACT
TABLE 13 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES FOR AI IN HEALTHCARE SECTOR
TABLE 14 AI IN HEALTHCARE MARKET: LIST OF PATENTS/PATENT APPLICATIONS, 2022–2024
TABLE 15 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 16 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 17 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 18 NORTH AMERICA
TABLE 19 EUROPE
TABLE 20 ASIA PACIFIC
TABLE 21 MIDDLE EAST & AFRICA
TABLE 22 LATIN AMERICA
TABLE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP 3 END USERS (%)
TABLE 24 KEY BUYING CRITERIA FOR TOP 3 END USERS
TABLE 25 UNMET NEEDS IN AI IN HEALTHCARE MARKET
TABLE 26 END-USER EXPECTATIONS IN AI IN HEALTHCARE MARKET
TABLE 27 EXPECTED CHANGE IN PRICES AND ANTICIPATED IMPACT ON END USERS DUE TO TARIFF IMPACT
TABLE 28 AI IN HEALTHCARE MARKET, BY FUNCTION, 2024–2031 (USD MILLION)
TABLE 29 AI IN HEALTHCARE MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2024–2031 (USD MILLION)
TABLE 30 AI IN HEALTHCARE MARKET FOR DIAGNOSIS & EARLY DETECTION, BY REGION, 2024–2031 (USD MILLION)
TABLE 31 AI IN HEALTHCARE MARKET FOR PRE-SCREENING, BY REGION, 2024–2031 (USD MILLION)
TABLE 32 AI IN HEALTHCARE MARKET FOR IVD, BY REGION, 2024–2031 (USD MILLION)
TABLE 33 AI IN HEALTHCARE MARKET FOR IVD, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 34 AI IN HEALTHCARE MARKET FOR IMMUNOASSAYS, BY REGION, 2024–2031 (USD MILLION)
TABLE 35 AI IN HEALTHCARE MARKET FOR CLINICAL CHEMISTRY, BY REGION, 2024–2031 (USD MILLION)
TABLE 36 AI IN HEALTHCARE MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION, 2024–2031 (USD MILLION)
TABLE 37 AI IN HEALTHCARE MARKET FOR IVD, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 38 AI IN HEALTHCARE MARKET FOR IMAGE ANALYSIS & INTERPRETATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 39 AI IN HEALTHCARE MARKET FOR BIOMARKER DISCOVERY & ANALYSIS, BY REGION, 2024–2031 (USD MILLION)
TABLE 40 AI IN HEALTHCARE MARKET FOR OTHER IVD APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 41 AI IN HEALTHCARE MARKET FOR DIAGNOSTIC IMAGING, BY REGION, 2024–2031 (USD MILLION)
TABLE 42 AI IN HEALTHCARE MARKET FOR DIAGNOSTIC IMAGING, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 43 AI IN HEALTHCARE MARKET FOR DISEASE INTERPRETATION & REPORT ANALYSIS, BY REGION, 2024–2031 (USD MILLION)
TABLE 44 AI IN HEALTHCARE MARKET FOR IMAGE CAPTIONING & ANNOTATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 45 AI IN HEALTHCARE MARKET FOR IMAGE RECONSTRUCTION, BY REGION, 2024–2031 (USD MILLION)
TABLE 46 AI IN HEALTHCARE MARKET FOR OTHER DIAGNOSTIC IMAGING, BY REGION, 2024–2031 (USD MILLION)
TABLE 47 AI IN HEALTHCARE MARKET FOR DIAGNOSTIC IMAGING, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 48 AI IN HEALTHCARE MARKET FOR MAGNETIC RESONANCE IMAGING, BY REGION, 2024–2031 (USD MILLION)
TABLE 49 AI IN HEALTHCARE MARKET FOR COMPUTED TOMOGRAPHY, BY REGION, 2024–2031 (USD MILLION)
TABLE 50 AI IN HEALTHCARE MARKET FOR X-RAY IMAGING, BY REGION,
2024–2031 (USD MILLION)
TABLE 51 AI IN HEALTHCARE MARKET FOR ULTRASOUND, BY REGION, 2024–2031 (USD MILLION)
TABLE 52 AI IN HEALTHCARE MARKET FOR NUCLEAR IMAGING, BY REGION, 2024–2031 (USD MILLION)
TABLE 53 AI IN HEALTHCARE MARKET FOR OTHER DIAGNOSTIC IMAGING MODALITIES,
BY REGION, 2024–2031 (USD MILLION)
TABLE 54 AI IN HEALTHCARE MARKET FOR RISK ASSESSMENT & PATIENT STRATIFICATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 55 AI IN HEALTHCARE MARKET FOR DRUG ALLERGY ALERTING, BY REGION, 2024–2031 (USD MILLION)
TABLE 56 AI IN HEALTHCARE MARKET FOR OTHER DIAGNOSIS & EARLY DETECTION FUNCTIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 57 AI IN HEALTHCARE MARKET FOR TREATMENT PLANNING & PERSONALIZATION,
BY TYPE, 2024–2031 (USD MILLION)
TABLE 58 AI IN HEALTHCARE MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 59 AI IN HEALTHCARE MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 60 AI IN HEALTHCARE MARKET FOR PERSONALIZED TREATMENT PLANNING, BY REGION, 2024–2031 (USD MILLION)
TABLE 61 AI IN HEALTHCARE MARKET FOR PRECISION MEDICINE & GENOMIC ANALYSIS, BY REGION, 2024–2031 (USD MILLION)
TABLE 62 AI IN HEALTHCARE MARKET FOR PREDICTIVE MODELS FOR TREATMENT RESPONSE, BY REGION, 2024–2031 (USD MILLION)
TABLE 63 AI IN HEALTHCARE MARKET FOR TREATMENT RECOMMENDATION SYSTEMS, BY REGION, 2024–2031 (USD MILLION)
TABLE 64 AI IN HEALTHCARE MARKET FOR PHARMACOLOGICAL THERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 65 AI IN HEALTHCARE MARKET FOR PHARMACOLOGICAL THERAPY, BY REGION, 2024–2031 (USD MILLION)
TABLE 66 AI IN HEALTHCARE MARKET FOR DRUG RESPONSE PREDICTION, BY REGION, 2024–2031 (USD MILLION)
TABLE 67 AI IN HEALTHCARE MARKET FOR DOSING & ADMINISTRATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 68 AI IN HEALTHCARE MARKET FOR OTHER PHARMACOLOGICAL THERAPY FUNCTIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 69 AI IN HEALTHCARE MARKET FOR SURGICAL THERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 70 AI IN HEALTHCARE MARKET FOR SURGICAL THERAPY, BY REGION, 2024–2031 (USD MILLION)
TABLE 71 AI IN HEALTHCARE MARKET FOR PREOPERATIVE IMAGING & 3D MODELING,
BY REGION, 2024–2031 (USD MILLION)
TABLE 72 AI IN HEALTHCARE MARKET FOR INTRAOPERATIVE GUIDANCE & ROBOTICS, BY REGION, 2024–2031 (USD MILLION)
TABLE 73 AI IN HEALTHCARE MARKET FOR POSTOPERATIVE ANALYSIS & RECOVERY,
BY REGION, 2024–2031 (USD MILLION)
TABLE 74 AI IN HEALTHCARE MARKET FOR RADIATION THERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 75 AI IN HEALTHCARE MARKET FOR RADIATION THERAPY, BY REGION, 2024–2031 (USD MILLION)
TABLE 76 AI IN HEALTHCARE MARKET FOR MOTION SYNCHRONIZATION & AUTO CONTOURING, BY REGION, 2024–2031 (USD MILLION)
TABLE 77 AI IN HEALTHCARE MARKET FOR REAL-TIME ADAPTIVE TREATMENT DELIVERY,
BY REGION, 2024–2031 (USD MILLION)
TABLE 78 AI IN HEALTHCARE MARKET FOR RESPONSE ASSESSMENT & QUALITY ASSURANCE, BY REGION, 2024–2031 (USD MILLION)
TABLE 79 AI IN HEALTHCARE MARKET FOR OTHER RADIATION THERAPY FUNCTIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 80 AI IN HEALTHCARE MARKET FOR BEHAVIORAL THERAPY & PSYCHOTHERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 81 AI IN HEALTHCARE MARKET FOR BEHAVIORAL THERAPY & PSYCHOTHERAPY, BY REGION, 2024–2031 (USD MILLION)
TABLE 82 AI IN HEALTHCARE MARKET FOR VIRTUAL COUNSELING & CHATBOTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 83 AI IN HEALTHCARE MARKET FOR PROGRESS MONITORING & FEEDBACK, BY REGION, 2024–2031 (USD MILLION)
TABLE 84 AI IN HEALTHCARE MARKET FOR FOLLOW-UP & LONG-TERM SUPPORT, BY REGION, 2024–2031 (USD MILLION)
TABLE 85 AI IN HEALTHCARE MARKET FOR IMMUNOTHERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 86 AI IN HEALTHCARE MARKET FOR IMMUNOTHERAPY, BY REGION, 2024–2031 (USD MILLION)
TABLE 87 AI IN HEALTHCARE MARKET FOR REAL-TIME PATIENT DATA MONITORING, BY REGION, 2024–2031 (USD MILLION)
TABLE 88 AI IN HEALTHCARE MARKET FOR RESPONSE & SIDE-EFFECT PREDICTION, BY REGION, 2024–2031 (USD MILLION)
TABLE 89 AI IN HEALTHCARE MARKET FOR RELAPSE PREDICTION & LONG-TERM MANAGEMENT, BY REGION, 2024–2031 (USD MILLION)
TABLE 90 AI IN HEALTHCARE MARKET FOR OTHER TREATMENT PLANNING & PERSONALIZATION FUNCTIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 91 AI IN HEALTHCARE MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 92 AI IN HEALTHCARE MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY REGION, 2024–2031 (USD MILLION)
TABLE 93 AI IN HEALTHCARE MARKET FOR SYMPTOM MANAGEMENT & VIRTUAL ASSISTANCE, BY REGION, 2024–2031 (USD MILLION)
TABLE 94 AI IN HEALTHCARE MARKET FOR TELEHEALTH & REMOTE PATIENT MONITORING, BY REGION, 2024–2031 (USD MILLION)
TABLE 95 AI IN HEALTHCARE MARKET FOR HEALTHCARE ASSISTANCE ROBOTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 96 AI IN HEALTHCARE MARKET FOR MEDICATION REMINDERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 97 AI IN HEALTHCARE MARKET FOR PATIENT EDUCATION & EMPOWERMENT, BY REGION, 2024–2031 (USD MILLION)
TABLE 98 AI IN HEALTHCARE MARKET FOR OTHER PATIENT ENGAGEMENT & REMOTE MONITORING FUNCTIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 99 AI IN HEALTHCARE MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2024–2031 (USD MILLION)
TABLE 100 AI IN HEALTHCARE MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY REGION, 2024–2031 (USD MILLION)
TABLE 101 AI IN HEALTHCARE MARKET FOR RECURRENCE MONITORING, BY REGION, 2024–2031 (USD MILLION)
TABLE 102 AI IN HEALTHCARE MARKET FOR LONG-TERM OUTCOME PREDICTION, BY REGION, 2024–2031 (USD MILLION)
TABLE 103 AI IN HEALTHCARE MARKET FOR MENTAL HEALTH & SUPPORT SYSTEMS, BY REGION, 2024–2031 (USD MILLION)
TABLE 104 AI IN HEALTHCARE MARKET FOR PHARMACY MANAGEMENT, BY TYPE, 2024–2031 (USD MILLION)
TABLE 105 AI IN HEALTHCARE MARKET FOR PHARMACY MANAGEMENT, BY REGION,
024–2031 (USD MILLION)
TABLE 106 AI IN HEALTHCARE MARKET FOR EPRESCRIBING, BY REGION, 2024–2031 (USD MILLION)
TABLE 107 AI IN HEALTHCARE MARKET FOR MEDICATION MANAGEMENT, BY REGION, 2024–2031 (USD MILLION)
TABLE 108 AI IN HEALTHCARE MARKET FOR PHARMACY AUDIT & ANALYSIS, BY REGION, 2024–2031 (USD MILLION)
TABLE 109 AI IN HEALTHCARE MARKET FOR OTHER PHARMACY MANAGEMENT FUNCTIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 110 AI IN HEALTHCARE MARKET FOR DATA MANAGEMENT & ANALYTICS FUNCTIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 111 AI IN HEALTHCARE MARKET FOR AI SCRIBE, BY REGION, 2024–2031 (USD MILLION)
TABLE 112 AI IN HEALTHCARE MARKET FOR CLINICAL DECISION SUPPORT SYSTEMS, BY REGION, 2024–2031 (USD MILLION)
TABLE 113 AI IN HEALTHCARE MARKET FOR ADMINISTRATIVE, BY TYPE,
2024–2031 (USD MILLION)
TABLE 114 AI IN HEALTHCARE MARKET FOR ADMINISTRATIVE, BY REGION, 2024–2031 (USD MILLION)
TABLE 115 AI IN HEALTHCARE MARKET FOR PATIENT REGISTRATION & SCHEDULING, BY REGION, 2024–2031 (USD MILLION)
TABLE 116 AI IN HEALTHCARE MARKET FOR PATIENT ELIGIBILITY & AUTHORIZATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 117 AI IN HEALTHCARE MARKET FOR REVENUE CYCLE MANAGEMENT, BY REGION, 2024–2031 (USD MILLION)
TABLE 118 AI IN HEALTHCARE MARKET FOR WORKFORCE MANAGEMENT, BY REGION, 2024–2031 (USD MILLION)
TABLE 119 AI IN HEALTHCARE MARKET FOR SUPPLY CHAIN & INVENTORY MANAGEMENT,
BY REGION, 2024–2031 (USD MILLION)
TABLE 120 AI IN HEALTHCARE MARKET FOR COMPLIANCE & DOCUMENTATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 121 AI IN HEALTHCARE MARKET FOR HEALTHCARE WORKFLOW MANAGEMENT, BY REGION, 2024–2031 (USD MILLION)
TABLE 122 AI IN HEALTHCARE MARKET FOR ASSET MANAGEMENT, BY REGION, 2024–2031 (USD MILLION)
TABLE 123 AI IN HEALTHCARE MARKET FOR CUSTOMER RELATIONSHIP MANAGEMENT, BY REGION, 2024–2031 (USD MILLION)
TABLE 124 AI IN HEALTHCARE MARKET FOR FRAUD DETECTION & RISK MANAGEMENT, BY REGION, 2024–2031 (USD MILLION)
TABLE 125 AI IN HEALTHCARE MARKET FOR CYBERSECURITY, BY REGION, 2024–2031 (USD MILLION)
TABLE 126 AI IN HEALTHCARE MARKET FOR OTHER ADMINISTRATIVE FUNCTIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 127 AI IN HEALTHCARE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 128 AI IN HEALTHCARE MARKET FOR INTEGRATED SOLUTIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 129 AI IN HEALTHCARE MARKET FOR NICHE/POINT SOLUTIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 130 AI IN HEALTHCARE MARKET FOR AI TECHNOLOGIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 131 AI IN HEALTHCARE MARKET FOR SERVICES, BY REGION,
2024–2031 (USD MILLION)
TABLE 132 AI IN HEALTHCARE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 133 AI IN HEALTHCARE MARKET FOR CLINICAL APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 134 AI IN HEALTHCARE MARKET FOR NON-CLINICAL APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 135 AI IN HEALTHCARE MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 136 AI IN HEALTHCARE MARKET FOR ON-PREMISES MODEL, BY REGION, 2024–2031 (USD MILLION)
TABLE 137 AI IN HEALTHCARE MARKET FOR CLOUD-BASED MODEL, BY REGION, 2024–2031 (USD MILLION)
TABLE 138 AI IN HEALTHCARE MARKET FOR HYBRID MODEL, BY REGION, 2024–2031 (USD MILLION)
TABLE 139 AI IN HEALTHCARE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 140 AI IN HEALTHCARE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 141 AI IN HEALTHCARE MARKET FOR MACHINE LEARNING, BY REGION, 2024–2031 (USD MILLION)
TABLE 142 AI IN HEALTHCARE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 143 AI IN HEALTHCARE MARKET FOR DEEP LEARNING, BY REGION, 2024–2031 (USD MILLION)
TABLE 144 AI IN HEALTHCARE MARKET FOR CONVOLUTIONAL NEURAL NETWORKS, BY REGION, 2024–2031 (USD MILLION)
TABLE 145 AI IN HEALTHCARE MARKET FOR RECURRENT NEURAL NETWORKS, BY REGION, 2024–2031 (USD MILLION)
TABLE 146 AI IN HEALTHCARE MARKET FOR GENERATIVE ADVERSARIAL NETWORKS, BY REGION, 2024–2031 (USD MILLION)
TABLE 147 AI IN HEALTHCARE MARKET FOR GRAPH NEURAL NETWORKS, BY REGION, 2024–2031 (USD MILLION)
TABLE 148 AI IN HEALTHCARE MARKET FOR OTHER DEEP LEARNING TOOLS, BY REGION, 2024–2031 (USD MILLION)
TABLE 149 AI IN HEALTHCARE MARKET FOR SUPERVISED LEARNING, BY REGION, 2024–2031 (USD MILLION)
TABLE 150 AI IN HEALTHCARE MARKET FOR REINFORCEMENT LEARNING, BY REGION, 2024–2031 (USD MILLION)
TABLE 151 AI IN HEALTHCARE MARKET FOR UNSUPERVISED LEARNING, BY REGION, 2024–2031 (USD MILLION)
TABLE 152 AI IN HEALTHCARE MARKET FOR OTHER MACHINE LEARNING TOOLS, BY REGION, 2024–2031 (USD MILLION)
TABLE 153 AI IN HEALTHCARE MARKET FOR NATURAL LANGUAGE PROCESSING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 154 AI IN HEALTHCARE MARKET FOR NATURAL LANGUAGE PROCESSING, BY REGION, 2024–2031 (USD MILLION)
TABLE 155 AI IN HEALTHCARE MARKET FOR SENTIMENT ANALYSIS, BY REGION, 2024–2031 (USD MILLION)
TABLE 156 AI IN HEALTHCARE MARKET FOR PATTERN & IMAGE RECOGNITION, BY REGION, 2024–2031 (USD MILLION)
TABLE 157 AI IN HEALTHCARE MARKET FOR AUTO CODING, BY REGION, 2024–2031 (USD MILLION)
TABLE 158 AI IN HEALTHCARE MARKET FOR CLASSIFICATION & CATEGORIZATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 159 AI IN HEALTHCARE MARKET FOR TEXT ANALYTICS, BY REGION, 2024–2031 (USD MILLION)
TABLE 160 AI IN HEALTHCARE MARKET FOR SPEECH RECOGNITION, BY REGION,
2024–2031 (USD MILLION)
TABLE 161 AI IN HEALTHCARE MARKET FOR CONTEXT-AWARE COMPUTING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 162 AI IN HEALTHCARE MARKET FOR CONTEXT-AWARE COMPUTING, BY REGION, 2024–2031 (USD MILLION)
TABLE 163 AI IN HEALTHCARE MARKET FOR DEVICE CONTEXT, BY REGION, 2024–2031 (USD MILLION)
TABLE 164 AI IN HEALTHCARE MARKET FOR USER CONTEXT, BY REGION, 2024–2031 (USD MILLION)
TABLE 165 AI IN HEALTHCARE MARKET FOR PHYSICAL CONTEXT, BY REGION, 2024–2031 (USD MILLION)
TABLE 166 AI IN HEALTHCARE MARKET FOR GENERATIVE AI, BY REGION, 2024–2031 (USD MILLION)
TABLE 167 AI IN HEALTHCARE MARKET FOR COMPUTER VISION, BY REGION, 2024–2031 (USD MILLION)
TABLE 168 AI IN HEALTHCARE MARKET FOR IMAGE ANALYSIS, BY REGION, 2024–2031 (USD MILLION)
TABLE 169 AI IN HEALTHCARE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 170 AI IN HEALTHCARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 171 AI IN HEALTHCARE MARKET FOR HEALTHCARE PROVIDERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 172 AI IN HEALTHCARE MARKET FOR HOSPITALS & CLINICS, BY REGION, 2024–2031 (USD MILLION)
TABLE 173 AI IN HEALTHCARE MARKET FOR AMBULATORY CARE CENTERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 174 AI IN HEALTHCARE MARKET FOR HOME HEALTHCARE AGENCIES & ASSISTED-LIVING FACILITIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 175 AI IN HEALTHCARE MARKET FOR DIAGNOSTIC & IMAGING CENTERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 176 AI IN HEALTHCARE MARKET FOR PHARMACIES, BY REGION,
2024–2031 (USD MILLION)
TABLE 177 AI IN HEALTHCARE MARKET FOR OTHER HEALTHCARE PROVIDERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 178 AI IN HEALTHCARE MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 179 AI IN HEALTHCARE MARKET FOR HEALTHCARE PAYERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 180 AI IN HEALTHCARE MARKET FOR PUBLIC PAYERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 181 AI IN HEALTHCARE MARKET FOR PRIVATE PAYERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 182 AI IN HEALTHCARE MARKET FOR PATIENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 183 AI IN HEALTHCARE MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 184 AI IN HEALTHCARE MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 185 NORTH AMERICA: AI IN HEALTHCARE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 186 NORTH AMERICA: AI IN HEALTHCARE MARKET, BY OFFERING,
2024–2031 (USD MILLION)
TABLE 187 NORTH AMERICA: AI IN HEALTHCARE MARKET, BY FUNCTION, 2024–2031 (USD MILLION)
TABLE 188 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2024–2031 (USD MILLION)
TABLE 189 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR IVD, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 190 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR IVD, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 191 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR DIAGNOSTIC IMAGING, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 192 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR DIAGNOSTIC IMAGING, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 193 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2024–2031 (USD MILLION)
TABLE 194 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 195 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR PHARMACOLOGICAL THERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 196 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR SURGICAL THERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 197 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR RADIATION THERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 198 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR BEHAVIORAL THERAPY & PSYCHOTHERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 199 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR IMMUNOTHERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 200 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 201 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2024–2031 (USD MILLION)
TABLE 202 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR PHARMACY MANAGEMENT, BY TYPE, 2024–2031 (USD MILLION)
TABLE 203 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR ADMINISTRATIVE, BY TYPE, 2024–2031 (USD MILLION)
TABLE 204 NORTH AMERICA: AI IN HEALTHCARE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 205 NORTH AMERICA: AI IN HEALTHCARE MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 206 NORTH AMERICA: AI IN HEALTHCARE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 207 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 208 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 209 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR NATURAL LANGUAGE PROCESSING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 210 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR CONTEXT-AWARE COMPUTING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 211 NORTH AMERICA: AI IN HEALTHCARE MARKET, BY END USER,
2024–2031 (USD MILLION)
TABLE 212 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 213 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 214 US: AI IN HEALTHCARE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 215 US: AI IN HEALTHCARE MARKET, BY FUNCTION, 2024–2031 (USD MILLION)
TABLE 216 US: AI IN HEALTHCARE MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2024–2031 (USD MILLION)
TABLE 217 US: AI IN HEALTHCARE MARKET FOR IVD, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 218 US: AI IN HEALTHCARE MARKET FOR IVD, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 219 US: AI IN HEALTHCARE MARKET FOR DIAGNOSTIC IMAGING, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 220 US: AI IN HEALTHCARE MARKET FOR DIAGNOSTIC IMAGING, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 221 US: AI IN HEALTHCARE MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2024–2031 (USD MILLION)
TABLE 222 US: AI IN HEALTHCARE MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 223 US: AI IN HEALTHCARE MARKET FOR PHARMACOLOGICAL THERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 224 US: AI IN HEALTHCARE MARKET FOR SURGICAL THERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 225 US: AI IN HEALTHCARE MARKET FOR RADIATION THERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 226 US: AI IN HEALTHCARE MARKET FOR BEHAVIORAL THERAPY & PSYCHOTHERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 227 US: AI IN HEALTHCARE MARKET FOR IMMUNOTHERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 228 US: AI IN HEALTHCARE MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 229 US: AI IN HEALTHCARE MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2024–2031 (USD MILLION)
TABLE 230 US: AI IN HEALTHCARE MARKET FOR PHARMACY MANAGEMENT, BY TYPE, 2024–2031 (USD MILLION)
TABLE 231 US: AI IN HEALTHCARE MARKET FOR ADMINISTRATIVE, BY TYPE, 2024–2031 (USD MILLION)
TABLE 232 US: AI IN HEALTHCARE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 233 US: AI IN HEALTHCARE MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 234 US: AI IN HEALTHCARE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 235 US: AI IN HEALTHCARE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 236 US: AI IN HEALTHCARE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 237 US: AI IN HEALTHCARE MARKET FOR NATURAL LANGUAGE PROCESSING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 238 US: AI IN HEALTHCARE MARKET FOR CONTEXT-AWARE COMPUTING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 239 US: AI IN HEALTHCARE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 240 US: AI IN HEALTHCARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 241 US: AI IN HEALTHCARE MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 242 CANADA: AI IN HEALTHCARE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 243 CANADA: AI IN HEALTHCARE MARKET, BY FUNCTION, 2024–2031 (USD MILLION)
TABLE 244 CANADA: AI IN HEALTHCARE MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2024–2031 (USD MILLION)
TABLE 245 CANADA: AI IN HEALTHCARE MARKET FOR IVD, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 246 CANADA: AI IN HEALTHCARE MARKET FOR IVD, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 247 CANADA: AI IN HEALTHCARE MARKET FOR DIAGNOSTIC IMAGING, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 248 CANADA: AI IN HEALTHCARE MARKET FOR DIAGNOSTIC IMAGING, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 249 CANADA: AI IN HEALTHCARE MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2024–2031 (USD MILLION)
TABLE 250 CANADA: AI IN HEALTHCARE MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 251 CANADA: AI IN HEALTHCARE MARKET FOR PHARMACOLOGICAL THERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 252 CANADA: AI IN HEALTHCARE MARKET FOR SURGICAL THERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 253 CANADA: AI IN HEALTHCARE MARKET FOR RADIATION THERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 254 CANADA: AI IN HEALTHCARE MARKET FOR BEHAVIORAL THERAPY & PSYCHOTHERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 255 CANADA: AI IN HEALTHCARE MARKET FOR IMMUNOTHERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 256 CANADA: AI IN HEALTHCARE MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 257 CANADA: AI IN HEALTHCARE MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2024–2031 (USD MILLION)
TABLE 258 CANADA: AI IN HEALTHCARE MARKET FOR PHARMACY MANAGEMENT, BY TYPE, 2024–2031 (USD MILLION)
TABLE 259 CANADA: AI IN HEALTHCARE MARKET FOR ADMINISTRATIVE, BY TYPE, 2024–2031 (USD MILLION)
TABLE 260 CANADA: AI IN HEALTHCARE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 261 CANADA: AI IN HEALTHCARE MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 262 CANADA: AI IN HEALTHCARE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 263 CANADA: AI IN HEALTHCARE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 264 CANADA: AI IN HEALTHCARE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 265 CANADA: AI IN HEALTHCARE MARKET FOR NATURAL LANGUAGE PROCESSING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 266 CANADA: AI IN HEALTHCARE MARKET FOR CONTEXT-AWARE COMPUTING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 267 CANADA: AI IN HEALTHCARE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 268 CANADA: AI IN HEALTHCARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 269 CANADA: AI IN HEALTHCARE MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 270 EUROPE: AI IN HEALTHCARE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 271 EUROPE: AI IN HEALTHCARE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 272 EUROPE: AI IN HEALTHCARE MARKET, BY FUNCTION, 2024–2031 (USD MILLION)
TABLE 273 EUROPE: AI IN HEALTHCARE MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2024–2031 (USD MILLION)
TABLE 274 EUROPE: AI IN HEALTHCARE MARKET FOR IVD, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 275 EUROPE: AI IN HEALTHCARE MARKET FOR IVD, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 276 EUROPE: AI IN HEALTHCARE MARKET FOR DIAGNOSTIC IMAGING, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 277 EUROPE: AI IN HEALTHCARE MARKET FOR DIAGNOSTIC IMAGING, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 278 EUROPE: AI IN HEALTHCARE MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2024–2031 (USD MILLION)
TABLE 279 EUROPE: AI IN HEALTHCARE MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 280 EUROPE: AI IN HEALTHCARE MARKET FOR PHARMACOLOGICAL THERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 281 EUROPE: AI IN HEALTHCARE MARKET FOR SURGICAL THERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 282 EUROPE: AI IN HEALTHCARE MARKET FOR RADIATION THERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 283 EUROPE: AI IN HEALTHCARE MARKET FOR BEHAVIORAL THERAPY & PSYCHOTHERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 284 EUROPE: AI IN HEALTHCARE MARKET FOR IMMUNOTHERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 285 EUROPE: AI IN HEALTHCARE MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 286 EUROPE: AI IN HEALTHCARE MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2024–2031 (USD MILLION)
TABLE 287 EUROPE: AI IN HEALTHCARE MARKET FOR PHARMACY MANAGEMENT, BY TYPE, 2024–2031 (USD MILLION)
TABLE 288 EUROPE: AI IN HEALTHCARE MARKET FOR ADMINISTRATIVE, BY TYPE, 2024–2031 (USD MILLION)
TABLE 289 EUROPE: AI IN HEALTHCARE MARKET, BY APPLICATION,
2024–2031 (USD MILLION)
TABLE 290 EUROPE: AI IN HEALTHCARE MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 291 EUROPE: AI IN HEALTHCARE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 292 EUROPE: AI IN HEALTHCARE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 293 EUROPE: AI IN HEALTHCARE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 294 EUROPE: AI IN HEALTHCARE MARKET FOR NATURAL LANGUAGE PROCESSING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 295 EUROPE: AI IN HEALTHCARE MARKET FOR CONTEXT-AWARE COMPUTING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 296 EUROPE: AI IN HEALTHCARE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 297 EUROPE: AI IN HEALTHCARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 298 EUROPE: AI IN HEALTHCARE MARKET FOR HEALTHCARE PAYERS, BY TYPE,
2024–2031 (USD MILLION)
TABLE 299 GERMANY: AI IN HEALTHCARE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 300 GERMANY: AI IN HEALTHCARE MARKET, BY FUNCTION, 2024–2031 (USD MILLION)
TABLE 301 GERMANY: AI IN HEALTHCARE MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2024–2031 (USD MILLION)
TABLE 302 GERMANY: AI IN HEALTHCARE MARKET FOR IVD, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 303 GERMANY: AI IN HEALTHCARE MARKET FOR IVD, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 304 GERMANY: AI IN HEALTHCARE MARKET FOR DIAGNOSTIC IMAGING, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 305 GERMANY: AI IN HEALTHCARE MARKET FOR DIAGNOSTIC IMAGING, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 306 GERMANY: AI IN HEALTHCARE MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2024–2031 (USD MILLION)
TABLE 307 GERMANY: AI IN HEALTHCARE MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 308 GERMANY: AI IN HEALTHCARE MARKET FOR PHARMACOLOGICAL THERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 309 GERMANY: AI IN HEALTHCARE MARKET FOR SURGICAL THERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 310 GERMANY: AI IN HEALTHCARE MARKET FOR RADIATION THERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 311 GERMANY: AI IN HEALTHCARE MARKET FOR BEHAVIORAL THERAPY & PSYCHOTHERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 312 GERMANY: AI IN HEALTHCARE MARKET FOR IMMUNOTHERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 313 GERMANY: AI IN HEALTHCARE MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 314 GERMANY: AI IN HEALTHCARE MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2024–2031 (USD MILLION)
TABLE 315 GERMANY: AI IN HEALTHCARE MARKET FOR PHARMACY MANAGEMENT, BY TYPE, 2024–2031 (USD MILLION)
TABLE 316 GERMANY: AI IN HEALTHCARE MARKET FOR ADMINISTRATIVE, BY TYPE,
2024–2031 (USD MILLION)
TABLE 317 GERMANY: AI IN HEALTHCARE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 318 GERMANY: AI IN HEALTHCARE MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 319 GERMANY: AI IN HEALTHCARE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 320 GERMANY: AI IN HEALTHCARE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 321 GERMANY: AI IN HEALTHCARE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 322 GERMANY: AI IN HEALTHCARE MARKET FOR NATURAL LANGUAGE PROCESSING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 323 GERMANY: AI IN HEALTHCARE MARKET FOR CONTEXT-AWARE COMPUTING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 324 GERMANY: AI IN HEALTHCARE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 325 GERMANY: AI IN HEALTHCARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 326 GERMANY: AI IN HEALTHCARE MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 1 INCLUSIONS AND EXCLUSIONS
TABLE 2 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
TABLE 3 AI IN HEALTHCARE MARKET: IMPACT ANALYSIS
TABLE 4 ARTIFICIAL INTELLIGENCE IN HEALTHCARE MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 5 AI IN HEALTHCARE MARKET: ROLE IN ECOSYSTEM
TABLE 6 INDICATIVE PRICING FOR AI IN HEALTHCARE, BY NON-CLINICAL APPLICATION (2025)
TABLE 7 INDICATIVE PRICING FOR AI IN HEALTHCARE, BY CLINICAL APPLICATION (2025)
TABLE 8 CASE 1: AI-ENABLED LUNG CANCER DIAGNOSIS IN NHS HOSPITALS
TABLE 9 CASE 2: AI-DRIVEN PATIENT ENGAGEMENT IN CHILDREN'S HEALTHCARE
TABLE 10 CASE 3: DIGITAL PATIENT ENGAGEMENT AT SPARTA COMMUNITY HOSPITAL
TABLE 11 US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 12 EXPECTED CHANGE IN PRICES AND LIKELY IMPACT ON END-USE MARKET DUE TO TARIFF IMPACT
TABLE 13 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES FOR AI IN HEALTHCARE SECTOR
TABLE 14 AI IN HEALTHCARE MARKET: LIST OF PATENTS/PATENT APPLICATIONS, 2022–2024
TABLE 15 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 16 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 17 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 18 NORTH AMERICA
TABLE 19 EUROPE
TABLE 20 ASIA PACIFIC
TABLE 21 MIDDLE EAST & AFRICA
TABLE 22 LATIN AMERICA
TABLE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP 3 END USERS (%)
TABLE 24 KEY BUYING CRITERIA FOR TOP 3 END USERS
TABLE 25 UNMET NEEDS IN AI IN HEALTHCARE MARKET
TABLE 26 END-USER EXPECTATIONS IN AI IN HEALTHCARE MARKET
TABLE 27 EXPECTED CHANGE IN PRICES AND ANTICIPATED IMPACT ON END USERS DUE TO TARIFF IMPACT
TABLE 28 AI IN HEALTHCARE MARKET, BY FUNCTION, 2024–2031 (USD MILLION)
TABLE 29 AI IN HEALTHCARE MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2024–2031 (USD MILLION)
TABLE 30 AI IN HEALTHCARE MARKET FOR DIAGNOSIS & EARLY DETECTION, BY REGION, 2024–2031 (USD MILLION)
TABLE 31 AI IN HEALTHCARE MARKET FOR PRE-SCREENING, BY REGION, 2024–2031 (USD MILLION)
TABLE 32 AI IN HEALTHCARE MARKET FOR IVD, BY REGION, 2024–2031 (USD MILLION)
TABLE 33 AI IN HEALTHCARE MARKET FOR IVD, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 34 AI IN HEALTHCARE MARKET FOR IMMUNOASSAYS, BY REGION, 2024–2031 (USD MILLION)
TABLE 35 AI IN HEALTHCARE MARKET FOR CLINICAL CHEMISTRY, BY REGION, 2024–2031 (USD MILLION)
TABLE 36 AI IN HEALTHCARE MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION, 2024–2031 (USD MILLION)
TABLE 37 AI IN HEALTHCARE MARKET FOR IVD, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 38 AI IN HEALTHCARE MARKET FOR IMAGE ANALYSIS & INTERPRETATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 39 AI IN HEALTHCARE MARKET FOR BIOMARKER DISCOVERY & ANALYSIS, BY REGION, 2024–2031 (USD MILLION)
TABLE 40 AI IN HEALTHCARE MARKET FOR OTHER IVD APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 41 AI IN HEALTHCARE MARKET FOR DIAGNOSTIC IMAGING, BY REGION, 2024–2031 (USD MILLION)
TABLE 42 AI IN HEALTHCARE MARKET FOR DIAGNOSTIC IMAGING, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 43 AI IN HEALTHCARE MARKET FOR DISEASE INTERPRETATION & REPORT ANALYSIS, BY REGION, 2024–2031 (USD MILLION)
TABLE 44 AI IN HEALTHCARE MARKET FOR IMAGE CAPTIONING & ANNOTATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 45 AI IN HEALTHCARE MARKET FOR IMAGE RECONSTRUCTION, BY REGION, 2024–2031 (USD MILLION)
TABLE 46 AI IN HEALTHCARE MARKET FOR OTHER DIAGNOSTIC IMAGING, BY REGION, 2024–2031 (USD MILLION)
TABLE 47 AI IN HEALTHCARE MARKET FOR DIAGNOSTIC IMAGING, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 48 AI IN HEALTHCARE MARKET FOR MAGNETIC RESONANCE IMAGING, BY REGION, 2024–2031 (USD MILLION)
TABLE 49 AI IN HEALTHCARE MARKET FOR COMPUTED TOMOGRAPHY, BY REGION, 2024–2031 (USD MILLION)
TABLE 50 AI IN HEALTHCARE MARKET FOR X-RAY IMAGING, BY REGION,
2024–2031 (USD MILLION)
TABLE 51 AI IN HEALTHCARE MARKET FOR ULTRASOUND, BY REGION, 2024–2031 (USD MILLION)
TABLE 52 AI IN HEALTHCARE MARKET FOR NUCLEAR IMAGING, BY REGION, 2024–2031 (USD MILLION)
TABLE 53 AI IN HEALTHCARE MARKET FOR OTHER DIAGNOSTIC IMAGING MODALITIES,
BY REGION, 2024–2031 (USD MILLION)
TABLE 54 AI IN HEALTHCARE MARKET FOR RISK ASSESSMENT & PATIENT STRATIFICATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 55 AI IN HEALTHCARE MARKET FOR DRUG ALLERGY ALERTING, BY REGION, 2024–2031 (USD MILLION)
TABLE 56 AI IN HEALTHCARE MARKET FOR OTHER DIAGNOSIS & EARLY DETECTION FUNCTIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 57 AI IN HEALTHCARE MARKET FOR TREATMENT PLANNING & PERSONALIZATION,
BY TYPE, 2024–2031 (USD MILLION)
TABLE 58 AI IN HEALTHCARE MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 59 AI IN HEALTHCARE MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 60 AI IN HEALTHCARE MARKET FOR PERSONALIZED TREATMENT PLANNING, BY REGION, 2024–2031 (USD MILLION)
TABLE 61 AI IN HEALTHCARE MARKET FOR PRECISION MEDICINE & GENOMIC ANALYSIS, BY REGION, 2024–2031 (USD MILLION)
TABLE 62 AI IN HEALTHCARE MARKET FOR PREDICTIVE MODELS FOR TREATMENT RESPONSE, BY REGION, 2024–2031 (USD MILLION)
TABLE 63 AI IN HEALTHCARE MARKET FOR TREATMENT RECOMMENDATION SYSTEMS, BY REGION, 2024–2031 (USD MILLION)
TABLE 64 AI IN HEALTHCARE MARKET FOR PHARMACOLOGICAL THERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 65 AI IN HEALTHCARE MARKET FOR PHARMACOLOGICAL THERAPY, BY REGION, 2024–2031 (USD MILLION)
TABLE 66 AI IN HEALTHCARE MARKET FOR DRUG RESPONSE PREDICTION, BY REGION, 2024–2031 (USD MILLION)
TABLE 67 AI IN HEALTHCARE MARKET FOR DOSING & ADMINISTRATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 68 AI IN HEALTHCARE MARKET FOR OTHER PHARMACOLOGICAL THERAPY FUNCTIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 69 AI IN HEALTHCARE MARKET FOR SURGICAL THERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 70 AI IN HEALTHCARE MARKET FOR SURGICAL THERAPY, BY REGION, 2024–2031 (USD MILLION)
TABLE 71 AI IN HEALTHCARE MARKET FOR PREOPERATIVE IMAGING & 3D MODELING,
BY REGION, 2024–2031 (USD MILLION)
TABLE 72 AI IN HEALTHCARE MARKET FOR INTRAOPERATIVE GUIDANCE & ROBOTICS, BY REGION, 2024–2031 (USD MILLION)
TABLE 73 AI IN HEALTHCARE MARKET FOR POSTOPERATIVE ANALYSIS & RECOVERY,
BY REGION, 2024–2031 (USD MILLION)
TABLE 74 AI IN HEALTHCARE MARKET FOR RADIATION THERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 75 AI IN HEALTHCARE MARKET FOR RADIATION THERAPY, BY REGION, 2024–2031 (USD MILLION)
TABLE 76 AI IN HEALTHCARE MARKET FOR MOTION SYNCHRONIZATION & AUTO CONTOURING, BY REGION, 2024–2031 (USD MILLION)
TABLE 77 AI IN HEALTHCARE MARKET FOR REAL-TIME ADAPTIVE TREATMENT DELIVERY,
BY REGION, 2024–2031 (USD MILLION)
TABLE 78 AI IN HEALTHCARE MARKET FOR RESPONSE ASSESSMENT & QUALITY ASSURANCE, BY REGION, 2024–2031 (USD MILLION)
TABLE 79 AI IN HEALTHCARE MARKET FOR OTHER RADIATION THERAPY FUNCTIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 80 AI IN HEALTHCARE MARKET FOR BEHAVIORAL THERAPY & PSYCHOTHERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 81 AI IN HEALTHCARE MARKET FOR BEHAVIORAL THERAPY & PSYCHOTHERAPY, BY REGION, 2024–2031 (USD MILLION)
TABLE 82 AI IN HEALTHCARE MARKET FOR VIRTUAL COUNSELING & CHATBOTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 83 AI IN HEALTHCARE MARKET FOR PROGRESS MONITORING & FEEDBACK, BY REGION, 2024–2031 (USD MILLION)
TABLE 84 AI IN HEALTHCARE MARKET FOR FOLLOW-UP & LONG-TERM SUPPORT, BY REGION, 2024–2031 (USD MILLION)
TABLE 85 AI IN HEALTHCARE MARKET FOR IMMUNOTHERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 86 AI IN HEALTHCARE MARKET FOR IMMUNOTHERAPY, BY REGION, 2024–2031 (USD MILLION)
TABLE 87 AI IN HEALTHCARE MARKET FOR REAL-TIME PATIENT DATA MONITORING, BY REGION, 2024–2031 (USD MILLION)
TABLE 88 AI IN HEALTHCARE MARKET FOR RESPONSE & SIDE-EFFECT PREDICTION, BY REGION, 2024–2031 (USD MILLION)
TABLE 89 AI IN HEALTHCARE MARKET FOR RELAPSE PREDICTION & LONG-TERM MANAGEMENT, BY REGION, 2024–2031 (USD MILLION)
TABLE 90 AI IN HEALTHCARE MARKET FOR OTHER TREATMENT PLANNING & PERSONALIZATION FUNCTIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 91 AI IN HEALTHCARE MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 92 AI IN HEALTHCARE MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY REGION, 2024–2031 (USD MILLION)
TABLE 93 AI IN HEALTHCARE MARKET FOR SYMPTOM MANAGEMENT & VIRTUAL ASSISTANCE, BY REGION, 2024–2031 (USD MILLION)
TABLE 94 AI IN HEALTHCARE MARKET FOR TELEHEALTH & REMOTE PATIENT MONITORING, BY REGION, 2024–2031 (USD MILLION)
TABLE 95 AI IN HEALTHCARE MARKET FOR HEALTHCARE ASSISTANCE ROBOTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 96 AI IN HEALTHCARE MARKET FOR MEDICATION REMINDERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 97 AI IN HEALTHCARE MARKET FOR PATIENT EDUCATION & EMPOWERMENT, BY REGION, 2024–2031 (USD MILLION)
TABLE 98 AI IN HEALTHCARE MARKET FOR OTHER PATIENT ENGAGEMENT & REMOTE MONITORING FUNCTIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 99 AI IN HEALTHCARE MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2024–2031 (USD MILLION)
TABLE 100 AI IN HEALTHCARE MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY REGION, 2024–2031 (USD MILLION)
TABLE 101 AI IN HEALTHCARE MARKET FOR RECURRENCE MONITORING, BY REGION, 2024–2031 (USD MILLION)
TABLE 102 AI IN HEALTHCARE MARKET FOR LONG-TERM OUTCOME PREDICTION, BY REGION, 2024–2031 (USD MILLION)
TABLE 103 AI IN HEALTHCARE MARKET FOR MENTAL HEALTH & SUPPORT SYSTEMS, BY REGION, 2024–2031 (USD MILLION)
TABLE 104 AI IN HEALTHCARE MARKET FOR PHARMACY MANAGEMENT, BY TYPE, 2024–2031 (USD MILLION)
TABLE 105 AI IN HEALTHCARE MARKET FOR PHARMACY MANAGEMENT, BY REGION,
024–2031 (USD MILLION)
TABLE 106 AI IN HEALTHCARE MARKET FOR EPRESCRIBING, BY REGION, 2024–2031 (USD MILLION)
TABLE 107 AI IN HEALTHCARE MARKET FOR MEDICATION MANAGEMENT, BY REGION, 2024–2031 (USD MILLION)
TABLE 108 AI IN HEALTHCARE MARKET FOR PHARMACY AUDIT & ANALYSIS, BY REGION, 2024–2031 (USD MILLION)
TABLE 109 AI IN HEALTHCARE MARKET FOR OTHER PHARMACY MANAGEMENT FUNCTIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 110 AI IN HEALTHCARE MARKET FOR DATA MANAGEMENT & ANALYTICS FUNCTIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 111 AI IN HEALTHCARE MARKET FOR AI SCRIBE, BY REGION, 2024–2031 (USD MILLION)
TABLE 112 AI IN HEALTHCARE MARKET FOR CLINICAL DECISION SUPPORT SYSTEMS, BY REGION, 2024–2031 (USD MILLION)
TABLE 113 AI IN HEALTHCARE MARKET FOR ADMINISTRATIVE, BY TYPE,
2024–2031 (USD MILLION)
TABLE 114 AI IN HEALTHCARE MARKET FOR ADMINISTRATIVE, BY REGION, 2024–2031 (USD MILLION)
TABLE 115 AI IN HEALTHCARE MARKET FOR PATIENT REGISTRATION & SCHEDULING, BY REGION, 2024–2031 (USD MILLION)
TABLE 116 AI IN HEALTHCARE MARKET FOR PATIENT ELIGIBILITY & AUTHORIZATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 117 AI IN HEALTHCARE MARKET FOR REVENUE CYCLE MANAGEMENT, BY REGION, 2024–2031 (USD MILLION)
TABLE 118 AI IN HEALTHCARE MARKET FOR WORKFORCE MANAGEMENT, BY REGION, 2024–2031 (USD MILLION)
TABLE 119 AI IN HEALTHCARE MARKET FOR SUPPLY CHAIN & INVENTORY MANAGEMENT,
BY REGION, 2024–2031 (USD MILLION)
TABLE 120 AI IN HEALTHCARE MARKET FOR COMPLIANCE & DOCUMENTATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 121 AI IN HEALTHCARE MARKET FOR HEALTHCARE WORKFLOW MANAGEMENT, BY REGION, 2024–2031 (USD MILLION)
TABLE 122 AI IN HEALTHCARE MARKET FOR ASSET MANAGEMENT, BY REGION, 2024–2031 (USD MILLION)
TABLE 123 AI IN HEALTHCARE MARKET FOR CUSTOMER RELATIONSHIP MANAGEMENT, BY REGION, 2024–2031 (USD MILLION)
TABLE 124 AI IN HEALTHCARE MARKET FOR FRAUD DETECTION & RISK MANAGEMENT, BY REGION, 2024–2031 (USD MILLION)
TABLE 125 AI IN HEALTHCARE MARKET FOR CYBERSECURITY, BY REGION, 2024–2031 (USD MILLION)
TABLE 126 AI IN HEALTHCARE MARKET FOR OTHER ADMINISTRATIVE FUNCTIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 127 AI IN HEALTHCARE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 128 AI IN HEALTHCARE MARKET FOR INTEGRATED SOLUTIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 129 AI IN HEALTHCARE MARKET FOR NICHE/POINT SOLUTIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 130 AI IN HEALTHCARE MARKET FOR AI TECHNOLOGIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 131 AI IN HEALTHCARE MARKET FOR SERVICES, BY REGION,
2024–2031 (USD MILLION)
TABLE 132 AI IN HEALTHCARE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 133 AI IN HEALTHCARE MARKET FOR CLINICAL APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 134 AI IN HEALTHCARE MARKET FOR NON-CLINICAL APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 135 AI IN HEALTHCARE MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 136 AI IN HEALTHCARE MARKET FOR ON-PREMISES MODEL, BY REGION, 2024–2031 (USD MILLION)
TABLE 137 AI IN HEALTHCARE MARKET FOR CLOUD-BASED MODEL, BY REGION, 2024–2031 (USD MILLION)
TABLE 138 AI IN HEALTHCARE MARKET FOR HYBRID MODEL, BY REGION, 2024–2031 (USD MILLION)
TABLE 139 AI IN HEALTHCARE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 140 AI IN HEALTHCARE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 141 AI IN HEALTHCARE MARKET FOR MACHINE LEARNING, BY REGION, 2024–2031 (USD MILLION)
TABLE 142 AI IN HEALTHCARE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 143 AI IN HEALTHCARE MARKET FOR DEEP LEARNING, BY REGION, 2024–2031 (USD MILLION)
TABLE 144 AI IN HEALTHCARE MARKET FOR CONVOLUTIONAL NEURAL NETWORKS, BY REGION, 2024–2031 (USD MILLION)
TABLE 145 AI IN HEALTHCARE MARKET FOR RECURRENT NEURAL NETWORKS, BY REGION, 2024–2031 (USD MILLION)
TABLE 146 AI IN HEALTHCARE MARKET FOR GENERATIVE ADVERSARIAL NETWORKS, BY REGION, 2024–2031 (USD MILLION)
TABLE 147 AI IN HEALTHCARE MARKET FOR GRAPH NEURAL NETWORKS, BY REGION, 2024–2031 (USD MILLION)
TABLE 148 AI IN HEALTHCARE MARKET FOR OTHER DEEP LEARNING TOOLS, BY REGION, 2024–2031 (USD MILLION)
TABLE 149 AI IN HEALTHCARE MARKET FOR SUPERVISED LEARNING, BY REGION, 2024–2031 (USD MILLION)
TABLE 150 AI IN HEALTHCARE MARKET FOR REINFORCEMENT LEARNING, BY REGION, 2024–2031 (USD MILLION)
TABLE 151 AI IN HEALTHCARE MARKET FOR UNSUPERVISED LEARNING, BY REGION, 2024–2031 (USD MILLION)
TABLE 152 AI IN HEALTHCARE MARKET FOR OTHER MACHINE LEARNING TOOLS, BY REGION, 2024–2031 (USD MILLION)
TABLE 153 AI IN HEALTHCARE MARKET FOR NATURAL LANGUAGE PROCESSING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 154 AI IN HEALTHCARE MARKET FOR NATURAL LANGUAGE PROCESSING, BY REGION, 2024–2031 (USD MILLION)
TABLE 155 AI IN HEALTHCARE MARKET FOR SENTIMENT ANALYSIS, BY REGION, 2024–2031 (USD MILLION)
TABLE 156 AI IN HEALTHCARE MARKET FOR PATTERN & IMAGE RECOGNITION, BY REGION, 2024–2031 (USD MILLION)
TABLE 157 AI IN HEALTHCARE MARKET FOR AUTO CODING, BY REGION, 2024–2031 (USD MILLION)
TABLE 158 AI IN HEALTHCARE MARKET FOR CLASSIFICATION & CATEGORIZATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 159 AI IN HEALTHCARE MARKET FOR TEXT ANALYTICS, BY REGION, 2024–2031 (USD MILLION)
TABLE 160 AI IN HEALTHCARE MARKET FOR SPEECH RECOGNITION, BY REGION,
2024–2031 (USD MILLION)
TABLE 161 AI IN HEALTHCARE MARKET FOR CONTEXT-AWARE COMPUTING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 162 AI IN HEALTHCARE MARKET FOR CONTEXT-AWARE COMPUTING, BY REGION, 2024–2031 (USD MILLION)
TABLE 163 AI IN HEALTHCARE MARKET FOR DEVICE CONTEXT, BY REGION, 2024–2031 (USD MILLION)
TABLE 164 AI IN HEALTHCARE MARKET FOR USER CONTEXT, BY REGION, 2024–2031 (USD MILLION)
TABLE 165 AI IN HEALTHCARE MARKET FOR PHYSICAL CONTEXT, BY REGION, 2024–2031 (USD MILLION)
TABLE 166 AI IN HEALTHCARE MARKET FOR GENERATIVE AI, BY REGION, 2024–2031 (USD MILLION)
TABLE 167 AI IN HEALTHCARE MARKET FOR COMPUTER VISION, BY REGION, 2024–2031 (USD MILLION)
TABLE 168 AI IN HEALTHCARE MARKET FOR IMAGE ANALYSIS, BY REGION, 2024–2031 (USD MILLION)
TABLE 169 AI IN HEALTHCARE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 170 AI IN HEALTHCARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 171 AI IN HEALTHCARE MARKET FOR HEALTHCARE PROVIDERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 172 AI IN HEALTHCARE MARKET FOR HOSPITALS & CLINICS, BY REGION, 2024–2031 (USD MILLION)
TABLE 173 AI IN HEALTHCARE MARKET FOR AMBULATORY CARE CENTERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 174 AI IN HEALTHCARE MARKET FOR HOME HEALTHCARE AGENCIES & ASSISTED-LIVING FACILITIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 175 AI IN HEALTHCARE MARKET FOR DIAGNOSTIC & IMAGING CENTERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 176 AI IN HEALTHCARE MARKET FOR PHARMACIES, BY REGION,
2024–2031 (USD MILLION)
TABLE 177 AI IN HEALTHCARE MARKET FOR OTHER HEALTHCARE PROVIDERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 178 AI IN HEALTHCARE MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 179 AI IN HEALTHCARE MARKET FOR HEALTHCARE PAYERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 180 AI IN HEALTHCARE MARKET FOR PUBLIC PAYERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 181 AI IN HEALTHCARE MARKET FOR PRIVATE PAYERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 182 AI IN HEALTHCARE MARKET FOR PATIENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 183 AI IN HEALTHCARE MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 184 AI IN HEALTHCARE MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 185 NORTH AMERICA: AI IN HEALTHCARE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 186 NORTH AMERICA: AI IN HEALTHCARE MARKET, BY OFFERING,
2024–2031 (USD MILLION)
TABLE 187 NORTH AMERICA: AI IN HEALTHCARE MARKET, BY FUNCTION, 2024–2031 (USD MILLION)
TABLE 188 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2024–2031 (USD MILLION)
TABLE 189 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR IVD, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 190 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR IVD, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 191 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR DIAGNOSTIC IMAGING, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 192 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR DIAGNOSTIC IMAGING, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 193 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2024–2031 (USD MILLION)
TABLE 194 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 195 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR PHARMACOLOGICAL THERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 196 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR SURGICAL THERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 197 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR RADIATION THERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 198 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR BEHAVIORAL THERAPY & PSYCHOTHERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 199 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR IMMUNOTHERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 200 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 201 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2024–2031 (USD MILLION)
TABLE 202 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR PHARMACY MANAGEMENT, BY TYPE, 2024–2031 (USD MILLION)
TABLE 203 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR ADMINISTRATIVE, BY TYPE, 2024–2031 (USD MILLION)
TABLE 204 NORTH AMERICA: AI IN HEALTHCARE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 205 NORTH AMERICA: AI IN HEALTHCARE MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 206 NORTH AMERICA: AI IN HEALTHCARE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 207 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 208 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 209 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR NATURAL LANGUAGE PROCESSING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 210 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR CONTEXT-AWARE COMPUTING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 211 NORTH AMERICA: AI IN HEALTHCARE MARKET, BY END USER,
2024–2031 (USD MILLION)
TABLE 212 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 213 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 214 US: AI IN HEALTHCARE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 215 US: AI IN HEALTHCARE MARKET, BY FUNCTION, 2024–2031 (USD MILLION)
TABLE 216 US: AI IN HEALTHCARE MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2024–2031 (USD MILLION)
TABLE 217 US: AI IN HEALTHCARE MARKET FOR IVD, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 218 US: AI IN HEALTHCARE MARKET FOR IVD, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 219 US: AI IN HEALTHCARE MARKET FOR DIAGNOSTIC IMAGING, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 220 US: AI IN HEALTHCARE MARKET FOR DIAGNOSTIC IMAGING, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 221 US: AI IN HEALTHCARE MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2024–2031 (USD MILLION)
TABLE 222 US: AI IN HEALTHCARE MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 223 US: AI IN HEALTHCARE MARKET FOR PHARMACOLOGICAL THERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 224 US: AI IN HEALTHCARE MARKET FOR SURGICAL THERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 225 US: AI IN HEALTHCARE MARKET FOR RADIATION THERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 226 US: AI IN HEALTHCARE MARKET FOR BEHAVIORAL THERAPY & PSYCHOTHERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 227 US: AI IN HEALTHCARE MARKET FOR IMMUNOTHERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 228 US: AI IN HEALTHCARE MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 229 US: AI IN HEALTHCARE MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2024–2031 (USD MILLION)
TABLE 230 US: AI IN HEALTHCARE MARKET FOR PHARMACY MANAGEMENT, BY TYPE, 2024–2031 (USD MILLION)
TABLE 231 US: AI IN HEALTHCARE MARKET FOR ADMINISTRATIVE, BY TYPE, 2024–2031 (USD MILLION)
TABLE 232 US: AI IN HEALTHCARE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 233 US: AI IN HEALTHCARE MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 234 US: AI IN HEALTHCARE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 235 US: AI IN HEALTHCARE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 236 US: AI IN HEALTHCARE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 237 US: AI IN HEALTHCARE MARKET FOR NATURAL LANGUAGE PROCESSING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 238 US: AI IN HEALTHCARE MARKET FOR CONTEXT-AWARE COMPUTING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 239 US: AI IN HEALTHCARE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 240 US: AI IN HEALTHCARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 241 US: AI IN HEALTHCARE MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 242 CANADA: AI IN HEALTHCARE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 243 CANADA: AI IN HEALTHCARE MARKET, BY FUNCTION, 2024–2031 (USD MILLION)
TABLE 244 CANADA: AI IN HEALTHCARE MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2024–2031 (USD MILLION)
TABLE 245 CANADA: AI IN HEALTHCARE MARKET FOR IVD, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 246 CANADA: AI IN HEALTHCARE MARKET FOR IVD, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 247 CANADA: AI IN HEALTHCARE MARKET FOR DIAGNOSTIC IMAGING, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 248 CANADA: AI IN HEALTHCARE MARKET FOR DIAGNOSTIC IMAGING, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 249 CANADA: AI IN HEALTHCARE MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2024–2031 (USD MILLION)
TABLE 250 CANADA: AI IN HEALTHCARE MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 251 CANADA: AI IN HEALTHCARE MARKET FOR PHARMACOLOGICAL THERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 252 CANADA: AI IN HEALTHCARE MARKET FOR SURGICAL THERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 253 CANADA: AI IN HEALTHCARE MARKET FOR RADIATION THERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 254 CANADA: AI IN HEALTHCARE MARKET FOR BEHAVIORAL THERAPY & PSYCHOTHERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 255 CANADA: AI IN HEALTHCARE MARKET FOR IMMUNOTHERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 256 CANADA: AI IN HEALTHCARE MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 257 CANADA: AI IN HEALTHCARE MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2024–2031 (USD MILLION)
TABLE 258 CANADA: AI IN HEALTHCARE MARKET FOR PHARMACY MANAGEMENT, BY TYPE, 2024–2031 (USD MILLION)
TABLE 259 CANADA: AI IN HEALTHCARE MARKET FOR ADMINISTRATIVE, BY TYPE, 2024–2031 (USD MILLION)
TABLE 260 CANADA: AI IN HEALTHCARE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 261 CANADA: AI IN HEALTHCARE MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 262 CANADA: AI IN HEALTHCARE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 263 CANADA: AI IN HEALTHCARE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 264 CANADA: AI IN HEALTHCARE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 265 CANADA: AI IN HEALTHCARE MARKET FOR NATURAL LANGUAGE PROCESSING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 266 CANADA: AI IN HEALTHCARE MARKET FOR CONTEXT-AWARE COMPUTING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 267 CANADA: AI IN HEALTHCARE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 268 CANADA: AI IN HEALTHCARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 269 CANADA: AI IN HEALTHCARE MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 270 EUROPE: AI IN HEALTHCARE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 271 EUROPE: AI IN HEALTHCARE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 272 EUROPE: AI IN HEALTHCARE MARKET, BY FUNCTION, 2024–2031 (USD MILLION)
TABLE 273 EUROPE: AI IN HEALTHCARE MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2024–2031 (USD MILLION)
TABLE 274 EUROPE: AI IN HEALTHCARE MARKET FOR IVD, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 275 EUROPE: AI IN HEALTHCARE MARKET FOR IVD, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 276 EUROPE: AI IN HEALTHCARE MARKET FOR DIAGNOSTIC IMAGING, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 277 EUROPE: AI IN HEALTHCARE MARKET FOR DIAGNOSTIC IMAGING, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 278 EUROPE: AI IN HEALTHCARE MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2024–2031 (USD MILLION)
TABLE 279 EUROPE: AI IN HEALTHCARE MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 280 EUROPE: AI IN HEALTHCARE MARKET FOR PHARMACOLOGICAL THERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 281 EUROPE: AI IN HEALTHCARE MARKET FOR SURGICAL THERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 282 EUROPE: AI IN HEALTHCARE MARKET FOR RADIATION THERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 283 EUROPE: AI IN HEALTHCARE MARKET FOR BEHAVIORAL THERAPY & PSYCHOTHERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 284 EUROPE: AI IN HEALTHCARE MARKET FOR IMMUNOTHERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 285 EUROPE: AI IN HEALTHCARE MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 286 EUROPE: AI IN HEALTHCARE MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2024–2031 (USD MILLION)
TABLE 287 EUROPE: AI IN HEALTHCARE MARKET FOR PHARMACY MANAGEMENT, BY TYPE, 2024–2031 (USD MILLION)
TABLE 288 EUROPE: AI IN HEALTHCARE MARKET FOR ADMINISTRATIVE, BY TYPE, 2024–2031 (USD MILLION)
TABLE 289 EUROPE: AI IN HEALTHCARE MARKET, BY APPLICATION,
2024–2031 (USD MILLION)
TABLE 290 EUROPE: AI IN HEALTHCARE MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 291 EUROPE: AI IN HEALTHCARE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 292 EUROPE: AI IN HEALTHCARE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 293 EUROPE: AI IN HEALTHCARE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 294 EUROPE: AI IN HEALTHCARE MARKET FOR NATURAL LANGUAGE PROCESSING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 295 EUROPE: AI IN HEALTHCARE MARKET FOR CONTEXT-AWARE COMPUTING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 296 EUROPE: AI IN HEALTHCARE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 297 EUROPE: AI IN HEALTHCARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 298 EUROPE: AI IN HEALTHCARE MARKET FOR HEALTHCARE PAYERS, BY TYPE,
2024–2031 (USD MILLION)
TABLE 299 GERMANY: AI IN HEALTHCARE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 300 GERMANY: AI IN HEALTHCARE MARKET, BY FUNCTION, 2024–2031 (USD MILLION)
TABLE 301 GERMANY: AI IN HEALTHCARE MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2024–2031 (USD MILLION)
TABLE 302 GERMANY: AI IN HEALTHCARE MARKET FOR IVD, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 303 GERMANY: AI IN HEALTHCARE MARKET FOR IVD, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 304 GERMANY: AI IN HEALTHCARE MARKET FOR DIAGNOSTIC IMAGING, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 305 GERMANY: AI IN HEALTHCARE MARKET FOR DIAGNOSTIC IMAGING, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 306 GERMANY: AI IN HEALTHCARE MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2024–2031 (USD MILLION)
TABLE 307 GERMANY: AI IN HEALTHCARE MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 308 GERMANY: AI IN HEALTHCARE MARKET FOR PHARMACOLOGICAL THERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 309 GERMANY: AI IN HEALTHCARE MARKET FOR SURGICAL THERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 310 GERMANY: AI IN HEALTHCARE MARKET FOR RADIATION THERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 311 GERMANY: AI IN HEALTHCARE MARKET FOR BEHAVIORAL THERAPY & PSYCHOTHERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 312 GERMANY: AI IN HEALTHCARE MARKET FOR IMMUNOTHERAPY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 313 GERMANY: AI IN HEALTHCARE MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 314 GERMANY: AI IN HEALTHCARE MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2024–2031 (USD MILLION)
TABLE 315 GERMANY: AI IN HEALTHCARE MARKET FOR PHARMACY MANAGEMENT, BY TYPE, 2024–2031 (USD MILLION)
TABLE 316 GERMANY: AI IN HEALTHCARE MARKET FOR ADMINISTRATIVE, BY TYPE,
2024–2031 (USD MILLION)
TABLE 317 GERMANY: AI IN HEALTHCARE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 318 GERMANY: AI IN HEALTHCARE MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 319 GERMANY: AI IN HEALTHCARE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 320 GERMANY: AI IN HEALTHCARE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 321 GERMANY: AI IN HEALTHCARE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 322 GERMANY: AI IN HEALTHCARE MARKET FOR NATURAL LANGUAGE PROCESSING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 323 GERMANY: AI IN HEALTHCARE MARKET FOR CONTEXT-AWARE COMPUTING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 324 GERMANY: AI IN HEALTHCARE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 325 GERMANY: AI IN HEALTHCARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 326 GERMANY: AI IN HEALTHCARE MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024–2031 (USD MILLION)
LIST OF FIGURES
FIGURE 1 MARKETS COVERED AND REGIONAL SCOPE
FIGURE 2 DURATION COVERED IN REPORT
FIGURE 3 MARKET SCENARIO
FIGURE 4 GLOBAL AI IN HEALTHCARE MARKET, 2024–2031
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN AI IN HEALTHCARE MARKET, 2023–2026
FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF AI IN HEALTHCARE MARKET
FIGURE 7 HIGH-GROWTH SEGMENTS IN AI IN HEALTHCARE MARKET, 2026–2031
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN AI IN HEALTHCARE MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
FIGURE 9 RAPID PROLIFERATION OF AI IN HOSPITALS TO DRIVE GROWTH OF AI IN HEALTHCARE MARKET
FIGURE 10 CLINICAL APPLICATIONS AND US ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2025
FIGURE 11 INDIA TO REGISTER HIGHEST GROWTH RATE IN GLOBAL AI IN HEALTHCARE MARKET DURING FORECAST PERIOD
FIGURE 12 AI IN HEALTHCARE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 13 AI IN HEALTHCARE MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 14 AI IN HEALTHCARE MARKET: VALUE CHAIN ANALYSIS
FIGURE 15 AI IN HEALTHCARE ECOSYSTEM ANALYSIS
FIGURE 16 TRENDS/DISRUPTIONS INFLUENCING CUSTOMER BUSINESSES
FIGURE 18 JURISDICTION AND TOP APPLICANT ANALYSIS FOR AI IN HEALTHCARE MARKET
FIGURE 19 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS) FOR AI IN HEALTHCARE MARKET (JANUARY 2015 TO DECEMBER 2025)
FIGURE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS
FIGURE 21 KEY BUYING CRITERIA FOR TOP 3 END USERS
FIGURE 22 NORTH AMERICA: AI IN HEALTHCARE MARKET SNAPSHOT
FIGURE 23 ASIA PACIFIC: AI IN HEALTHCARE MARKET SNAPSHOT
FIGURE 24 REVENUE ANALYSIS OF KEY PLAYERS IN AI IN HEALTHCARE MARKET, 2021–2025
FIGURE 25 MARKET SHARE ANALYSIS OF KEY PLAYERS IN AI IN HEALTHCARE MARKET, 2025
FIGURE 26 AI IN HEALTHCARE MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 27 AI IN HEALTHCARE MARKET: COMPANY FOOTPRINT, 2025
FIGURE 28 AI IN HEALTHCARE MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 29 EV/EBITDA OF KEY VENDORS, 2026
FIGURE 30 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2026
FIGURE 31 AI IN HEALTHCARE MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
FIGURE 32 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT
FIGURE 33 MICROSOFT CORPORATION: COMPANY SNAPSHOT
FIGURE 34 NVIDIA CORPORATION: COMPANY SNAPSHOT
FIGURE 35 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT
FIGURE 36 GE HEALTHCARE: COMPANY SNAPSHOT
FIGURE 37 ORACLE: COMPANY SNAPSHOT
FIGURE 38 AMAZON WEB SERVICES, INC.: COMPANY SNAPSHOT
FIGURE 39 IBM: COMPANY SNAPSHOT
FIGURE 40 MEDTRONIC: COMPANY SNAPSHOT
FIGURE 41 GOOGLE: COMPANY SNAPSHOT
FIGURE 42 SOPHIA GENETICS: COMPANY SNAPSHOT
FIGURE 43 JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT
FIGURE 44 TEMPUS: COMPANY SNAPSHOT
FIGURE 45 SOLVENTUM CORPORATION: COMPANY SNAPSHOT
FIGURE 46 COGNIZANT: COMPANY SNAPSHOT
FIGURE 47 RESEARCH DESIGN
FIGURE 48 KEY DATA FROM SECONDARY SOURCES
FIGURE 49 PRIMARY SOURCES
FIGURE 50 KEY INSIGHTS FROM INDUSTRY EXPERTS
FIGURE 51 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE), BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 52 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 53 BOTTOM-UP APPROACH: END USER SPENDING ON AI IN HEALTHCARE
FIGURE 54 AI IN HEALTHCARE MARKET: CAGR PROJECTION FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 55 CAGR PROJECTION: SUPPLY-SIDE ANALYSIS
FIGURE 56 TOP-DOWN APPROACH
FIGURE 57 DATA TRIANGULATION METHODOLOGY
FIGURE 1 MARKETS COVERED AND REGIONAL SCOPE
FIGURE 2 DURATION COVERED IN REPORT
FIGURE 3 MARKET SCENARIO
FIGURE 4 GLOBAL AI IN HEALTHCARE MARKET, 2024–2031
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN AI IN HEALTHCARE MARKET, 2023–2026
FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF AI IN HEALTHCARE MARKET
FIGURE 7 HIGH-GROWTH SEGMENTS IN AI IN HEALTHCARE MARKET, 2026–2031
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN AI IN HEALTHCARE MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
FIGURE 9 RAPID PROLIFERATION OF AI IN HOSPITALS TO DRIVE GROWTH OF AI IN HEALTHCARE MARKET
FIGURE 10 CLINICAL APPLICATIONS AND US ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2025
FIGURE 11 INDIA TO REGISTER HIGHEST GROWTH RATE IN GLOBAL AI IN HEALTHCARE MARKET DURING FORECAST PERIOD
FIGURE 12 AI IN HEALTHCARE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 13 AI IN HEALTHCARE MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 14 AI IN HEALTHCARE MARKET: VALUE CHAIN ANALYSIS
FIGURE 15 AI IN HEALTHCARE ECOSYSTEM ANALYSIS
FIGURE 16 TRENDS/DISRUPTIONS INFLUENCING CUSTOMER BUSINESSES
FIGURE 18 JURISDICTION AND TOP APPLICANT ANALYSIS FOR AI IN HEALTHCARE MARKET
FIGURE 19 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS) FOR AI IN HEALTHCARE MARKET (JANUARY 2015 TO DECEMBER 2025)
FIGURE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS
FIGURE 21 KEY BUYING CRITERIA FOR TOP 3 END USERS
FIGURE 22 NORTH AMERICA: AI IN HEALTHCARE MARKET SNAPSHOT
FIGURE 23 ASIA PACIFIC: AI IN HEALTHCARE MARKET SNAPSHOT
FIGURE 24 REVENUE ANALYSIS OF KEY PLAYERS IN AI IN HEALTHCARE MARKET, 2021–2025
FIGURE 25 MARKET SHARE ANALYSIS OF KEY PLAYERS IN AI IN HEALTHCARE MARKET, 2025
FIGURE 26 AI IN HEALTHCARE MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 27 AI IN HEALTHCARE MARKET: COMPANY FOOTPRINT, 2025
FIGURE 28 AI IN HEALTHCARE MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 29 EV/EBITDA OF KEY VENDORS, 2026
FIGURE 30 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2026
FIGURE 31 AI IN HEALTHCARE MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
FIGURE 32 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT
FIGURE 33 MICROSOFT CORPORATION: COMPANY SNAPSHOT
FIGURE 34 NVIDIA CORPORATION: COMPANY SNAPSHOT
FIGURE 35 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT
FIGURE 36 GE HEALTHCARE: COMPANY SNAPSHOT
FIGURE 37 ORACLE: COMPANY SNAPSHOT
FIGURE 38 AMAZON WEB SERVICES, INC.: COMPANY SNAPSHOT
FIGURE 39 IBM: COMPANY SNAPSHOT
FIGURE 40 MEDTRONIC: COMPANY SNAPSHOT
FIGURE 41 GOOGLE: COMPANY SNAPSHOT
FIGURE 42 SOPHIA GENETICS: COMPANY SNAPSHOT
FIGURE 43 JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT
FIGURE 44 TEMPUS: COMPANY SNAPSHOT
FIGURE 45 SOLVENTUM CORPORATION: COMPANY SNAPSHOT
FIGURE 46 COGNIZANT: COMPANY SNAPSHOT
FIGURE 47 RESEARCH DESIGN
FIGURE 48 KEY DATA FROM SECONDARY SOURCES
FIGURE 49 PRIMARY SOURCES
FIGURE 50 KEY INSIGHTS FROM INDUSTRY EXPERTS
FIGURE 51 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE), BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 52 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 53 BOTTOM-UP APPROACH: END USER SPENDING ON AI IN HEALTHCARE
FIGURE 54 AI IN HEALTHCARE MARKET: CAGR PROJECTION FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 55 CAGR PROJECTION: SUPPLY-SIDE ANALYSIS
FIGURE 56 TOP-DOWN APPROACH
FIGURE 57 DATA TRIANGULATION METHODOLOGY
